Main Menu

Publications Highlights View all by category

Types of Publications


Journal Articles

Larkin, J., Brown, M.P., Arance, A.M., Hauschild, A., Queirolo, P., Vecchio, M.D., Ascierto, P.A., Krajsová, I., Schachter, J., Neyns, B., et al. (2019). An open-label, multicentre safety study of vemurafenib in patients with BRAFV600-mutant metastatic melanoma: final analysis and a validated prognostic scoring system. European journal of cancer, Vol.107, pp. 175-185.

Larkin, J., Minor, D., D'Angelo, S., Neyns, B., Smylie, M., Miller, W.H., Gutzmer, R., Linette, G., Chmielowski, B., Lao, C.D., et al. (2018). Overall Survival in Patients With Advanced Melanoma Who Received Nivolumab Versus Investigator’s Choice Chemotherapy in CheckMate 037: A Randomized, Controlled, Open-Label Phase III Trial. Journal of clinical oncology, Vol.36 (4), pp. 383-390.

Lim, K.H., Spain, L., Barker, C., Georgiou, A., Walls, G., Gore, M., Turajlic, S., Board, R., Larkin, J.M. & Lorigan, P., et al. (2018). Contemporary outcomes from the use of regular imaging to detect relapse in high-risk cutaneous melanoma. Esmo open, Vol.3 (2), pp. e000317-e000317.

Smith, H.G., Joshi, K., Strauss, D.C., Hayes, A.J., Larkin, J. & Smith, M.J. (2018). The Impact of Effective Systemic Therapies on Surgery for Stage IV Metastatic Melanoma. Annals of surgical oncology, Vol.25, pp. S41-S41.

Grob, J.J., Schadendorf, D., Lorigan, P., Ascierto, P., Larkin, J., Nathan, P., Robert, C., Hauschild, A., Weber, J., Daud, A., et al. (2018). Eighth American Joint Committee on Cancer (AJCC) melanoma classification: Let us reconsider stage III. European journal of cancer, Vol.91, pp. 168-170.

Valpione, S., Carlino, M.S., Mangana, J., Mooradian, M.J., McArthur, G., Schadendorf, D., Hauschild, A., Menzies, A.M., Arance, A., Ascierto, P.A., et al. (2018). Rechallenge with BRAF-directed treatment in metastatic melanoma: A multi-institutional retrospective study. European journal of cancer, Vol.91, pp. 116-124.

Dréno, B., Ascierto, P.A., Atkinson, V., Liszkay, G., Maio, M., Mandalà, M., Demidov, L., Stroyakovskiy, D., Thomas, L., de la Cruz-Merino, L., et al. (2018). Health-related quality of life impact of cobimetinib in combination with vemurafenib in patients with advanced or metastatic BRAFV600 mutation–positive melanoma. British journal of cancer, Vol.118 (6), pp. 777-784.

Hayes, A.J. & Larkin, J. (2018). BMI and outcomes in melanoma: more evidence for the obesity paradox. The lancet oncology, Vol.19 (3), pp. 269-270.

Yip, K., Melcher, A., Harrington, K., Illidge, T., Nobes, J., Webster, A., Smith, D., Lorigan, P., Nathan, P. & Larkin, J., et al. (2018). Pembrolizumab in Combination with Radiotherapy for Metastatic Melanoma — Introducing the PERM Trial. Clinical oncology, Vol.30 (4), pp. 201-203.

Choueiri, T.K., Larkin, J., Oya, M., Thistlethwaite, F., Martignoni, M., Nathan, P., Powles, T., McDermott, D., Robbins, P.B., Chism, D.D., et al. (2018). Preliminary results for avelumab plus axitinib as first-line therapy in patients with advanced clear-cell renal-cell carcinoma (JAVELIN Renal 100): an open-label, dose-finding and dose-expansion, phase 1b trial. The lancet oncology, Vol.19 (4), pp. 451-460.

Arce Vargas, F., Furness, A.J., Litchfield, K., Joshi, K., Rosenthal, R., Ghorani, E., Solomon, I., Lesko, M.H., Ruef, N., Roddie, C., et al. (2018). Fc Effector Function Contributes to the Activity of Human Anti-CTLA-4 Antibodies. Cancer cell, Vol.33 (4), pp. 649-663.e4.

Turajlic, S., Xu, H., Litchfield, K., Rowan, A., Horswell, S., Chambers, T., O’Brien, T., Lopez, J.I., Watkins, T.B., Nicol, D., et al. (2018). Deterministic Evolutionary Trajectories Influence Primary Tumor Growth: TRACERx Renal. Cell, Vol.173 (3), pp. 595-610.e11.

Turajlic, S., Xu, H., Litchfield, K., Rowan, A., Chambers, T., Lopez, J.I., Nicol, D., O’Brien, T., Larkin, J., Horswell, S., et al. (2018). Tracking Cancer Evolution Reveals Constrained Routes to Metastases: TRACERx Renal. Cell, Vol.173 (3), pp. 581-594.e12.

Mitchell, T.J., Turajlic, S., Rowan, A., Nicol, D., Farmery, J.H., O’Brien, T., Martincorena, I., Tarpey, P., Angelopoulos, N., Yates, L.R., et al. (2018). Timing the Landmark Events in the Evolution of Clear Cell Renal Cell Cancer: TRACERx Renal. Cell, Vol.173 (3), pp. 611-623.e17.

Wongchenko, M.J., Ribas, A., Dréno, B., Ascierto, P.A., McArthur, G.A., Gallo, J.D., Rooney, I.A., Hsu, J., Koeppen, H., Yan, Y., et al. (2018). Association of programmed death ligand-1 (PD-L1) expression with treatment outcomes in patients with BRAF mutation-positive melanoma treated with vemurafenib or cobimetinib combined with vemurafenib. Pigment cell & melanoma research, Vol.31 (4), pp. 516-522.

Eggermont, A.M., Blank, C.U., Mandala, M., Long, G.V., Atkinson, V., Dalle, S., Haydon, A., Lichinitser, M., Khattak, A., Carlino, M.S., et al. (2018). Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma. New england journal of medicine, Vol.378 (19), pp. 1789-1801.

Sun, M., Marconi, L., Eisen, T., Escudier, B., Giles, R.H., Haas, N.B., Harshman, L.C., Quinn, D.I., Larkin, J., Pal, S.K., et al. (2018). Adjuvant Vascular Endothelial Growth Factor–targeted Therapy in Renal Cell Carcinoma: A Systematic Review and Pooled Analysis. European urology, Vol.74 (5), pp. 611-620.

Spain, L., Walls, G., Messiou, C., Turajlic, S., Gore, M. & Larkin, J. (2017). Efficacy and toxicity of rechallenge with combination immune checkpoint blockade in metastatic melanoma: a case series. Cancer immunology, immunotherapy, Vol.66 (1), pp. 113-117.

Long, G.V., Flaherty, K.T., Stroyakovskiy, D., Gogas, H., Levchenko, E., de Braud, F., Larkin, J., Garbe, C., Jouary, T., Hauschild, A., et al. (2017). Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study. Annals of oncology, Vol.28 (7), pp. 1631-1639.

Wongchenko, M.J., McArthur, G.A., Dréno, B., Larkin, J., Ascierto, P.A., Sosman, J., Andries, L., Kockx, M., Hurst, S.D., Caro, I., et al. (2017). Gene Expression Profiling in BRAF-Mutated Melanoma Reveals Patient Subgroups with Poor Outcomes to Vemurafenib That May Be Overcome by Cobimetinib Plus Vemurafenib. Clinical cancer research, Vol.23 (17), pp. 5238-5245.

Long, G.V., Weber, J.S., Larkin, J., Atkinson, V., Grob, J.-., Schadendorf, D., Dummer, R., Robert, C., Márquez-Rodas, I., McNeil, C., et al. (2017). Nivolumab for Patients With Advanced Melanoma Treated Beyond Progression. Jama oncology, Vol.3 (11), pp. 1511-1511.

Haanen, J.B., Carbonnel, F., Robert, C., Kerr, K.M., Peters, S., Larkin, J. & Jordan, K. (2017). Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†. Annals of oncology, Vol.28 (suppl_4), pp. iv119-iv142.

Chapman, P.B., Robert, C., Larkin, J., Haanen, J.B., Ribas, A., Hogg, D., Hamid, O., Ascierto, P.A., Testori, A., Lorigan, P.C., et al. (2017). Vemurafenib in patients with BRAFV600 mutation-positive metastatic melanoma: final overall survival results of the randomized BRIM-3 study. Ann oncol, Vol.28 (10), pp. 2581-2587.  show abstract

Grande, E., Glen, H., Aller, J., Argenziano, G., Lamas, M.J., Ruszniewski, P., Zamorano, J.L., Edmonds, K., Sarker, S., Staehler, M., et al. (2017). Recommendations on managing lenvatinib and everolimus in patients with advanced or metastatic renal cell carcinoma. Expert opinion on drug safety, Vol.16 (12), pp. 1413-1426.

Weber, J.S., Hodi, F.S., Wolchok, J.D., Topalian, S.L., Schadendorf, D., Larkin, J., Sznol, M., Long, G.V., Li, H., Waxman, I.M., et al. (2017). Safety Profile of Nivolumab Monotherapy: A Pooled Analysis of Patients With Advanced Melanoma. Journal of clinical oncology, Vol.35 (7), pp. 785-792.

O’reilly, A. & Larkin, J. (2017). Checkpoint inhibitors in advanced melanoma: effect on the field of immunotherapy. Expert review of anticancer therapy, Vol.17 (7), pp. 647-655.

O’Reilly, A. & Larkin, J. (2017). The safety of nivolumab for the treatment of metastatic melanoma. Expert opinion on drug safety, Vol.16 (8), pp. 955-961.

Rothermundt, C., von Rappard, J., Eisen, T., Escudier, B., Grünwald, V., Larkin, J., McDermott, D., Oldenburg, J., Porta, C., Rini, B., et al. (2017). Second-line treatment for metastatic clear cell renal cell cancer: experts’ consensus algorithms. World journal of urology, Vol.35 (4), pp. 641-648.

Morganstein, D.L., Lai, Z., Spain, L., Diem, S., Levine, D., Mace, C., Gore, M. & Larkin, J. (2017). Thyroid abnormalities following the use of cytotoxic T-lymphocyte antigen-4 and programmed death receptor protein-1 inhibitors in the treatment of melanoma. Clinical endocrinology, Vol.86 (4), pp. 614-620.

Bracarda, S., Negrier, S., Casper, J., Porta, C., Schmidinger, M., Larkin, J., Gross Goupil, M. & Escudier, B. (2017). How clinical practice is changing the rules: the sunitinib 2/1 schedule in metastatic renal cell carcinoma. Expert review of anticancer therapy, Vol.17 (3), pp. 227-233.

Spain, L., Schmid, T., Gore, M. & Larkin, J. (2017). Efficacy of the combination of ipilimumab and nivolumab following progression on pembrolizumab in advanced melanoma with poor risk features. European journal of cancer, Vol.75, pp. 243-244.

Bowyer, S., Prithviraj, P., Lorigan, P., Larkin, J., McArthur, G., Atkinson, V., Millward, M., Khou, M., Diem, S., Ramanujam, S., et al. (2017). Reply to ‘Comment on ‘Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy’’. British journal of cancer, Vol.116 (8), pp. e15-e15.

Arce Vargas, F., Furness, A.J., Solomon, I., Joshi, K., Mekkaoui, L., Lesko, M.H., Miranda Rota, E., Dahan, R., Georgiou, A., Sledzinska, A., et al. (2017). Fc-Optimized Anti-CD25 Depletes Tumor-Infiltrating Regulatory T Cells and Synergizes with PD-1 Blockade to Eradicate Established Tumors. Immunity, Vol.46 (4), pp. 577-586.

Dreno, B., Ribas, A., Larkin, J., Ascierto, P.A., Hauschild, A., Thomas, L., Grob, J.-., Koralek, D.O., Rooney, I., Hsu, J.J., et al. (2017). Incidence, course, and management of toxicities associated with cobimetinib in combination with vemurafenib in the coBRIM study. Annals of oncology, Vol.28 (5), pp. 1137-1144.

Wolchok, J.D., Chiarion-Sileni, V., Gonzalez, R., Rutkowski, P., Grob, J.-., Cowey, C.L., Lao, C.D., Wagstaff, J., Schadendorf, D., Ferrucci, P.F., et al. (2017). Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma. New england journal of medicine, Vol.377 (14), pp. 1345-1356.

Stewart, G.D., Aitchison, M., Bex, A., Larkin, J., Lawless, C., Méjean, A., Nathan, P., Oades, G., Patard, J.-., Paul, J., et al. (2017). Cytoreductive Nephrectomy in the Tyrosine Kinase Inhibitor Era: A Question That May Never Be Answered. European urology, Vol.71 (6), pp. 845-847.

Larkin, J., Chmielowski, B., Lao, C.D., Hodi, F.S., Sharfman, W., Weber, J., Suijkerbuijk, K.P., Azevedo, S., Li, H., Reshef, D., et al. (2017). Neurologic Serious Adverse Events Associated with Nivolumab Plus Ipilimumab or Nivolumab Alone in Advanced Melanoma, Including a Case Series of Encephalitis. The oncologist, Vol.22 (6), pp. 709-718.

Helgadottir, H., Kis, L., Ljungman, P., Larkin, J., Kefford, R., Ascierto, P.A., Hansson, J. & Masucci, G. (2017). Lethal aplastic anemia caused by dual immune checkpoint blockade in metastatic melanoma. Annals of oncology, Vol.28 (7), pp. 1672-1673.

Blank, C.U., Larkin, J., Arance, A.M., Hauschild, A., Queirolo, P., Del Vecchio, M., Ascierto, P.A., Krajsova, I., Schachter, J., Neyns, B., et al. (2017). Open-label, multicentre safety study of vemurafenib in 3219 patients with BRAF V600 mutation-positive metastatic melanoma: 2-year follow-up data and long-term responders' analysis. European journal of cancer, Vol.79, pp. 176-184.

Colomba, E., Le Teuff, G., Eisen, T., Stewart, G.D., Fife, K., Larkin, J., Biondo, A., Pickering, L., Srinivasan, A., Boyle, H., et al. (2017). Metastatic chromophobe renal cell carcinoma treated with targeted therapies: A Renal Cross Channel Group study. European journal of cancer, Vol.80, pp. 55-62.

Scelo, G., Purdue, M.P., Brown, K.M., Johansson, M., Wang, Z., Eckel-Passow, J.E., Ye, Y., Hofmann, J.N., Choi, J., Foll, M., et al. (2017). Genome-wide association study identifies multiple risk loci for renal cell carcinoma. Nature communications, Vol.8 (1).

Turajlic, S., Litchfield, K., Xu, H., Rosenthal, R., McGranahan, N., Reading, J.L., Wong, Y.N., Rowan, A., Kanu, N., Al Bakir, M., et al. (2017). Insertion-and-deletion-derived tumour-specific neoantigens and the immunogenic phenotype: a pan-cancer analysis. The lancet oncology, Vol.18 (8), pp. 1009-1021.

Matoori, S., Thian, Y., Koh, D.-., Sohaib, A., Larkin, J., Pickering, L. & Gutzeit, A. (2017). Contrast-Enhanced CT Density Predicts Response to Sunitinib Therapy in Metastatic Renal Cell Carcinoma Patients. Translational oncology, Vol.10 (4), pp. 679-685.

Schadendorf, D., Larkin, J., Wolchok, J., Hodi, F.S., Chiarion-Sileni, V., Gonzalez, R., Rutkowski, P., Grob, J.-., Cowey, C.L., Lao, C., et al. (2017). Health-related quality of life results from the phase III CheckMate 067 study. European journal of cancer, Vol.82, pp. 80-91.

Ugurel, S., Röhmel, J., Ascierto, P.A., Flaherty, K.T., Grob, J.J., Hauschild, A., Larkin, J., Long, G.V., Lorigan, P., McArthur, G.A., et al. (2017). Survival of patients with advanced metastatic melanoma: the impact of novel therapies–update 2017. European journal of cancer, Vol.83, pp. 247-257.

Long, G.V., Hauschild, A., Santinami, M., Atkinson, V., Mandalà, M., Chiarion-Sileni, V., Larkin, J., Nyakas, M., Dutriaux, C., Haydon, A., et al. (2017). Adjuvant Dabrafenib plus Trametinib in Stage IIIBRAF-Mutated Melanoma. New england journal of medicine, Vol.377 (19), pp. 1813-1823.

Weber, J., Mandala, M., Del Vecchio, M., Gogas, H.J., Arance, A.M., Cowey, C.L., Dalle, S., Schenker, M., Chiarion-Sileni, V., Marquez-Rodas, I., et al. (2017). Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma. New england journal of medicine, Vol.377 (19), pp. 1824-1835.

D’Angelo, S.P., Larkin, J., Sosman, J.A., Lebbé, C., Brady, B., Neyns, B., Schmidt, H., Hassel, J.C., Hodi, F.S., Lorigan, P., et al. (2017). Efficacy and Safety of Nivolumab Alone or in Combination With Ipilimumab in Patients With Mucosal Melanoma: A Pooled Analysis. Journal of clinical oncology, Vol.35 (2), pp. 226-235.

Schachter, J., Ribas, A., Long, G.V., Arance, A., Grob, J.-., Mortier, L., Daud, A., Carlino, M.S., McNeil, C., Lotem, M., et al. (2017). Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006). The lancet, Vol.390 (10105), pp. 1853-1862.

Machiela, M.J., Hofmann, J.N., Carreras-Torres, R., Brown, K.M., Johansson, M., Wang, Z., Foll, M., Li, P., Rothman, N., Savage, S.A., et al. (2017). Genetic Variants Related to Longer Telomere Length are Associated with Increased Risk of Renal Cell Carcinoma. European urology, Vol.72 (5), pp. 747-754.

Hsieh, J.J., Purdue, M.P., Signoretti, S., Swanton, C., Albiges, L., Schmidinger, M., Heng, D.Y., Larkin, J. & Ficarra, V. (2017). Renal cell carcinoma. Nature reviews disease primers, Vol.3 (1).

de la Cruz-Merino, L., Di Guardo, L., Grob, J.-., Venosa, A., Larkin, J., McArthur, G.A., Ribas, A., Ascierto, P.A., Evans, J.T., Gomez-Escobar, A., et al. (2017). Clinical features of serous retinopathy observed with cobimetinib in patients with BRAF-mutated melanoma treated in the randomized coBRIM study. Journal of translational medicine, Vol.15 (1).

Schadendorf, D., Wolchok, J.D., Hodi, F.S., Chiarion-Sileni, V., Gonzalez, R., Rutkowski, P., Grob, J.-., Cowey, C.L., Lao, C.D., Chesney, J., et al. (2017). Efficacy and Safety Outcomes in Patients With Advanced Melanoma Who Discontinued Treatment With Nivolumab and Ipilimumab Because of Adverse Events: A Pooled Analysis of Randomized Phase II and III Trials. Journal of clinical oncology, Vol.35 (34), pp. 3807-3814.

(2017). Nivolumab and Ipilimumab in Advanced Melanoma. New england journal of medicine, Vol.377 (25), pp. 2503-2504.

Flynn, M.J. & Larkin, J.M. (2017). Novel combination strategies for enhancing efficacy of immune checkpoint inhibitors in the treatment of metastatic solid malignancies. Expert opinion on pharmacotherapy, Vol.18 (14), pp. 1477-1490.

Seifert, H., Hirata, E., Gore, M., Khabra, K., Messiou, C., Larkin, J. & Sahai, E. (2016). Extrinsic factors can mediate resistance to BRAF inhibition in central nervous system melanoma metastases. Pigment cell & melanoma research, Vol.29 (1), pp. 92-100.

Bridgeman, V., Wan, E., Foo, S., Nathan, M., Welti, J., Frentzas, S., Vermeulen, P., Preece, N., Springer, C., Powles, T., et al. (2016). Preclinical evidence that trametinib enhances the response to anti-angiogenic tyrosine kinase inhibitors in renal cell carcinoma. Molecular cancer therapeutics, Vol.1 (15), pp. 172-183.

Ugurel, S., Röhmel, J., Ascierto, P.A., Flaherty, K.T., Grob, J.J., Hauschild, A., Larkin, J., Long, G.V., Lorigan, P., McArthur, G.A., et al. (2016). Survival of patients with advanced metastatic melanoma: The impact of novel therapies. European journal of cancer, Vol.53, pp. 125-134.

Motzer, R.J., Hutson, T.E., Ren, M., Dutcus, C. & Larkin, J. (2016). Independent assessment of lenvatinib plus everolimus in patients with metastatic renal cell carcinoma. The lancet oncology, Vol.17 (1), pp. e4-e5.

Atkins, M.B. & Larkin, J. (2016). Immunotherapy Combined or Sequenced With Targeted Therapy in the Treatment of Solid Tumors: Current Perspectives. Jnci: journal of the national cancer institute, Vol.108 (6).

Porta, C., Tortora, G., Larkin, J.M. & Hutson, T.E. (2016). Management of poor-risk metastatic renal cell carcinoma: current approaches, the role of temsirolimus and future directions. Future oncology, Vol.12 (4), pp. 533-549.

Diem, S., Kasenda, B., Spain, L., Martin-Liberal, J., Marconcini, R., Gore, M. & Larkin, J. (2016). Serum lactate dehydrogenase as an early marker for outcome in patients treated with anti-PD-1 therapy in metastatic melanoma. British journal of cancer, Vol.114 (3), pp. 256-261.

Spain, L., Julve, M. & Larkin, J. (2016). Combination dabrafenib and trametinib in the management of advanced melanoma with BRAFV600 mutations. Expert opinion on pharmacotherapy, Vol.17 (7), pp. 1031-1038.

Spain, L. & Larkin, J. (2016). Combination immune checkpoint blockade with ipilimumab and nivolumab in the management of advanced melanoma. Expert opinion on biological therapy, Vol.16 (3), pp. 389-396.

Spain, L., Diem, S. & Larkin, J. (2016). Management of toxicities of immune checkpoint inhibitors. Cancer treatment reviews, Vol.44, pp. 51-60.

Thomas, C.L., Mortimer, P.S., Larkin, J.M., Basu, T.N., Gore, M.E. & Fearfield, L. (2016). A mitogen-activated protein kinase kinase inhibitor induced compound skin toxicity with oedema in metastatic malignant melanoma. Clinical and experimental dermatology, Vol.41 (3), pp. 267-271.

Seifert, H., Fisher, R., Martin-Liberal, J., Edmonds, K., Hughes, P., Khabra, K., Gore, M. & Larkin, J. (2016). Prognostic markers and tumour growth kinetics in melanoma patients progressing on vemurafenib. Melanoma research, Vol.26 (2), pp. 138-144.

Gravis, G., Chanez, B., Derosa, L., Beuselinck, B., Barthelemy, P., Laguerre, B., Brachet, P.-., Joly, F., Escudier, B., Harrison, D.J., et al. (2016). Effect of glandular metastases on overall survival of patients with metastatic clear cell renal cell carcinoma in the antiangiogenic therapy era. Urologic oncology: seminars and original investigations, Vol.34 (4), pp. 167.e17-167.e23.

Powles, T., Brown, J., Larkin, J., Jones, R., Ralph, C., Hawkins, R., Chowdhury, S., Boleti, E., Bhal, A., Fife, K., et al. (2016). A randomized, double-blind phase II study evaluating cediranib versus cediranib and saracatinib in patients with relapsed metastatic clear-cell renal cancer (COSAK). Annals of oncology, Vol.27 (5), pp. 880-886.

Bowyer, S., Prithviraj, P., Lorigan, P., Larkin, J., McArthur, G., Atkinson, V., Millward, M., Khou, M., Diem, S., Ramanujam, S., et al. (2016). Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy. British journal of cancer, Vol.114 (10), pp. 1084-1089.

Spain, L., Higgins, R., Gopalakrishnan, K., Turajlic, S., Gore, M. & Larkin, J. (2016). Acute renal allograft rejection after immune checkpoint inhibitor therapy for metastatic melanoma. Annals of oncology, Vol.27 (6), pp. 1135-1137.

Spain, L., Larkin, J. & Martin-Liberal, J. (2016). Determining predictive factors for immune checkpoint inhibitor toxicity: Response to Letter to the Editors “A case report of insulin-dependent diabetes as immune-related toxicity of pembrolizumab: presentation, management and outcome”. Cancer immunology, immunotherapy, Vol.65 (6), pp. 769-770.

Spain, L. & Larkin, J. (2016). Weighing up the pros and cons of immune checkpoint inhibitors in the treatment of melanoma. Immunotherapy, Vol.8 (6), pp. 677-679.

Rini, B.I., Dorff, T.B., Elson, P., Rodriguez, C.S., Shepard, D., Wood, L., Humbert, J., Pyle, L., Wong, Y.-., Finke, J.H., et al. (2016). Active surveillance in metastatic renal-cell carcinoma: a prospective, phase 2 trial. The lancet oncology, Vol.17 (9), pp. 1317-1324.

Ascierto, P.A., McArthur, G.A., Dréno, B., Atkinson, V., Liszkay, G., Di Giacomo, A.M., Mandalà, M., Demidov, L., Stroyakovskiy, D., Thomas, L., et al. (2016). Cobimetinib combined with vemurafenib in advanced BRAFV600-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial. The lancet oncology, Vol.17 (9), pp. 1248-1260.

Spain, L., Goode, E., McGovern, Y., Joshi, K. & Larkin, J. (2016). The combination of vemurafenib and cobimetinib in advanced melanoma. Expert opinion on orphan drugs, Vol.4 (11), pp. 1105-1111.

Turajlic, S. & Larkin, J. (2016). Systemic treatment of advanced papillary renal cell carcinoma: Where next?. European journal of cancer, Vol.69, pp. 223-225.

Joshi, K., Furness, A.J., Oakes, T., Heather, J., Spain, L.A., Wong, Y.N., Ben Aissa, A., Stares, M., Smith, M.J., Strauss, D.C., et al. (2016). Defining the mechanisms of response and resistance to anti-PD-1 therapy: An exploratory phase II study of pembrolizumab in advanced melanoma (ADAPTeM). Journal of clinical oncology, Vol.34 (15_suppl), pp. TPS9599-TPS9599.

Spain, L., Walls, G., Julve, M., O'Meara, K., Schmid, T., Kalaitzaki, E., Turajlic, S., Gore, M., Rees, J. & Larkin, J., et al. (2016). Neurotoxicity from immune-checkpoint inhibition in the treatment of melanoma: a single centre experience and review of the literature. Ann oncol, .

Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J.-., Cowey, C.L., Lao, C.D., Wagstaff, J., Hogg, D., Hill, A., Carlino, M.S., et al. (2016). Efficacy and safety in key patient subgroups of nivolumab (NIVO) alone or combined with ipilimumab (IPI) versus IPI alone in treatment-naive patients with advanced melanoma (MEL) (CheckMate 067). Oncology research and treatment, Vol.39, pp. 40-40.

Lorigan, P., Ascierto, P.A., Dummer, R., Eggermont, A.M., Flaherty, K.T., Garbe, C., Gogas, H., Hauschild, A., Kefford, R.F., Kirkwood, J.M., et al. (2015). Expanded access programmes: patient interests versus clinical trial integrity. Lancet oncology, Vol.16 (1), pp. 15-17.

Larkin, J., Lao, C.D., Urba, W.J., McDermott, D.F., Horak, C., Jiang, J. & Wolchok, J.D. (2015). Efficacy and Safety of Nivolumab in Patients With BRAF V600 Mutant and BRAF Wild-Type Advanced Melanoma. Jama oncology, Vol.1 (4), pp. 433-433.

Rothermundt, C., Bailey, A., Cerbone, L., Eisen, T., Escudier, B., Gillessen, S., Grunwald, V., Larkin, J., McDermott, D., Oldenburg, J., et al. (2015). Algorithms in the First-Line Treatment of Metastatic Clear Cell Renal Cell Carcinoma--Analysis Using Diagnostic Nodes. The oncologist, Vol.20 (9), pp. 1028-1035.

Coupe, N., Corrie, P., Hategan, M., Larkin, J., Gore, M., Gupta, A., Wise, A., Suter, S., Ciria, C., Love, S., et al. (2015). PACMEL: a phase 1 dose escalation trial of trametinib (GSK1120212) in combination with paclitaxel. Eur j cancer, Vol.51 (3), pp. 359-366.  show abstract

Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J.J., Cowey, C.L., Lao, C.D., Schadendorf, D., Dummer, R., Smylie, M., Rutkowski, P., et al. (2015). Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. New england journal of medicine, Vol.373 (1), pp. 23-34.

Larkin, J., Paine, A., Foley, G., Mitchell, S. & Chen, C. (2015). First-line treatment in the management of advanced renal cell carcinoma: systematic review and network meta-analysis. Expert opinion on pharmacotherapy, Vol.16 (13), pp. 1915-1927.

Martin-Liberal, J., Kordbacheh, T. & Larkin, J. (2015). Safety of pembrolizumab for the treatment of melanoma. Expert opinion on drug safety, Vol.14 (6), pp. 957-964.

Weber, J.S., D'Angelo, S.P., Minor, D., Hodi, F.S., Gutzmer, R., Neyns, B., Hoeller, C., Khushalani, N.I., Miller, W.H., Lao, C.D., et al. (2015). Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. The lancet oncology, Vol.16 (4), pp. 375-384.

Sinha, R., Larkin, J. & Fearfield, L. (2015). Clinical resolution of vemurafenib-induced squamous cell carcinoma with topical 5-fluorouracil. British journal of dermatology, Vol.172 (4), pp. 1135-1136.

Hirata, E., Girotti, M.R., Viros, A., Hooper, S., Spencer-Dene, B., Matsuda, M., Larkin, J., Marais, R. & Sahai, E. (2015). Intravital Imaging Reveals How BRAF Inhibition Generates Drug-Tolerant Microenvironments with High Integrin β1/FAK Signaling. Cancer cell, Vol.27 (4), pp. 574-588.

Kovac, M., Navas, C., Horswell, S., Salm, M., Bardella, C., Rowan, A., Stares, M., Castro-Giner, F., Fisher, R., de Bruin, E.C., et al. (2015). Recurrent chromosomal gains and heterogeneous driver mutations characterise papillary renal cancer evolution. Nature communications, Vol.6 (1).

Schadendorf, D., Amonkar, M.M., Stroyakovskiy, D., Levchenko, E., Gogas, H., de Braud, F., Grob, J.-., Bondarenko, I., Garbe, C., Lebbe, C., et al. (2015). Health-related quality of life impact in a randomised phase III study of the combination of dabrafenib and trametinib versus dabrafenib monotherapy in patients with BRAF V600 metastatic melanoma. European journal of cancer, Vol.51 (7), pp. 833-840.

Thomas, C.L., Mortimer, P.S., Larkin, J.M., Basu, T.N., Gore, M.E. & Fearfield, L. (2015). MEK-inhibitor induced compound skin toxicity with oedema in metastatic malignant melanoma: a case series. Australasian journal of dermatology, Vol.56, pp. 78-78.

Bex, A., Larkin, J. & Voss, M. (2015). Challenging the Treatment Paradigm for Advanced Renal Cell Carcinoma: A Review of Systemic and Localized Therapies. American society of clinical oncology educational book, (35), pp. e239-e247.

Motzer, R.J., Escudier, B., McDermott, D.F., George, S., Hammers, H.J., Srinivas, S., Tykodi, S.S., Sosman, J.A., Procopio, G., Plimack, E.R., et al. (2015). Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. New england journal of medicine, Vol.373 (19), pp. 1803-1813.

Martin-Liberal, J., Furness, A.J., Joshi, K., Peggs, K.S., Quezada, S.A. & Larkin, J. (2015). Anti-programmed cell death-1 therapy and insulin-dependent diabetes: a case report. Cancer immunology, immunotherapy, Vol.64 (6), pp. 765-767.

Yousaf, N., Davidson, M., Goode, E., Thomas, C., Hung, R., Gore, M. & Larkin, J. (2015). The cost of ipilimumab toxicity. Melanoma research, Vol.25 (3), pp. 259-264.

Pickering, L.M. & Larkin, J. (2015). Carbonic anhydrase IX in resected clear cell RCC. Nature reviews urology, Vol.12 (6), pp. 309-310.

Long, G.V., Stroyakovskiy, D., Gogas, H., Levchenko, E., de Braud, F., Larkin, J., Garbe, C., Jouary, T., Hauschild, A., Grob, J.-., et al. (2015). Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial. The lancet, Vol.386 (9992), pp. 444-451.

Wolchok, J.D., Chiarion-Sileni, V., Gonzalez, R., Rutkowski, P., Grob, J.J., Cowey, C.L., Lao, C.D., Schadendorf, D., Ferrucci, P.F., Smylie, M., et al. (2015). CHECKMATE 067: A PHASE III RANDOMIZED DOUBLE-BLIND STUDY OF NIVOLUMAB (NIVO) MONOTHERAPY OR NIVO COMBINED WITH IPILIMUMAB (IPI) VERSUS IPI MONOTHERAPY IN PREVIOUSLY UNTREATED PATIENTS (PTS) WITH ADVANCED MELANOMA (MEL). Asia-pacific journal of clinical oncology, Vol.11, pp. 68-68.

Gulati, S., Turajlic, S., Larkin, J., Bates, P.A. & Swanton, C. (2015). Relapse models for clear cell renal carcinoma. The lancet oncology, Vol.16 (8), pp. e376-e378.

(2015). Corrigendum. The journal of pathology, Vol.236 (4), pp. 531-531.

Moriceau, G., Hugo, W., Hong, A., Shi, H., Kong, X., Yu, C.C., Koya, R.C., Samatar, A.A., Khanlou, N., Braun, J., et al. (2015). Tunable-combinatorial mechanisms of acquired resistance limit the efficacy of BRAF/MEK cotargeting but result in melanoma drug addiction. Cancer cell, Vol.27 (2), pp. 240-256.  show abstract

Soultati, A., Stares, M., Swanton, C., Larkin, J. & Turajlic, S. (2015). How should clinicians address intratumour heterogeneity in clear cell renal cell carcinoma?. Current opinion in urology, Vol.25 (5), pp. 358-366.

Sinha, R., Larkin, J., Gore, M. & Fearfield, L. (2015). Cutaneous toxicities associated with vemurafenib therapy in 107 patients withBRAFV600E mutation-positive metastatic melanoma, including recognition and management of rare presentations. British journal of dermatology, Vol.173 (4), pp. 1024-1031.

Turajlic, S., Larkin, J. & Swanton, C. (2015). Academically led clinical trials: challenges and opportunities: Figure 1. Annals of oncology, Vol.26 (10), pp. 2010-2011.

Ahmad, S.S., Qian, W., Ellis, S., Mason, E., Khattak, M.A., Gupta, A., Shaw, H., Quinton, A., Kovarikova, J., Thillai, K., et al. (2015). Ipilimumab in the real world. Melanoma research, Vol.25 (5), pp. 432-442.

Motzer, R., Hutson, T., Glen, H., Michaelson, M.D., Molina, A., Eisen, T., Jassem, J., Zolnierek, J., Maroto, P., Mellado, B., et al. (2015). Randomized phase 2 three-arm trial of lenvatinib (LEN), everolimus (EVE), and LEN plus EVE in patients (pts) with metastatic renal cell carcinoma (mRCC). Oncology research and treatment, Vol.38, pp. 203-204.

Kanu, N., Grönroos, E., Martinez, P., Burrell, R.A., Yi Goh, X., Bartkova, J., Maya-Mendoza, A., Mistrík, M., Rowan, A.J., Patel, H., et al. (2015). SETD2 loss-of-function promotes renal cancer branched evolution through replication stress and impaired DNA repair. Oncogene, Vol.34 (46), pp. 5699-5708.

Motzer, R.J., Hutson, T.E., Glen, H., Michaelson, M.D., Molina, A., Eisen, T., Jassem, J., Zolnierek, J., Maroto, J.P., Mellado, B., et al. (2015). Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial. The lancet oncology, Vol.16 (15), pp. 1473-1482.

Wilkins, A., Furness, A., W Corbett, R., Bloomfield, A., Porta, N., Morris, S., Ali, Z., Larkin, J. & Harrington, K. (2015). The melanoma-specific graded prognostic assessment does not adequately discriminate prognosis in a modern population with brain metastases from malignant melanoma. British journal of cancer, Vol.113 (9), pp. 1275-1281.

Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J.-., Cowey, C.L., Lao, C.D., Wagstaff, J., Hogg, D., Hill, A., Carlino, M.S., et al. (2015). EFFICACY AND SAFETY IN KEY PATIENT SUBGROUPS OF NIVOLUMAB (NIVO) ALONE OR COMBINED WITH IPILIMUMAB (IPI) VERSUS IPI ALONE IN TREATMENT-NAIVE PATIENTS WITH ADVANCED MELANOMA (MEL) (CHECKMATE 067). Asia-pacific journal of clinical oncology, Vol.11, pp. 126-126.

Dummer, R., Schadendorf, D., Ascierto, P.A., Larkin, J., Lebbé, C. & Hauschild, A. (2015). Integrating first-line treatment options into clinical practice. Melanoma research, Vol.25 (6), pp. 461-469.

Diem, S., Kasenda, B., Martin-Liberal, J., Lee, A., Chauhan, D., Gore, M. & Larkin, J. (2015). Prognostic score for patients with advanced melanoma treated with ipilimumab. European journal of cancer, Vol.51 (18), pp. 2785-2791.

Turajlic, S., Larkin, J. & Swanton, C. (2015). SnapShot: Renal Cell Carcinoma. Cell, Vol.163 (6), pp. 1556-1556.e1.

Gore, M. & Larkin, J. (2015). Precision oncology: where next?. The lancet oncology, Vol.16 (16), pp. 1593-1595.

Richman, J., Martin-Liberal, J., Diem, S. & Larkin, J. (2015). BRAF and MEK inhibition for the treatment of advanced BRAF mutant melanoma. Expert opinion on pharmacotherapy, Vol.16 (9), pp. 1285-1297.

Jamal-Hanjani, M., Quezada, S.A., Larkin, J. & Swanton, C. (2015). Translational Implications of Tumor Heterogeneity. Clinical cancer research, Vol.21 (6), pp. 1258-1266.

(2015). Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. New england journal of medicine, Vol.373 (13), pp. 1270-1271.

Robert, C., Schachter, J., Long, G.V., Arance, A., Grob, J.J., Mortier, L., Daud, A., Carlino, M.S., McNeil, C., Lotem, M., et al. (2015). Pembrolizumab versus Ipilimumab in Advanced Melanoma. New england journal of medicine, Vol.372 (26), pp. 2521-2532.

Martin-Liberal, J. & Larkin, J. (2015). Vemurafenib for the treatment of BRAF mutant metastatic melanoma. Future oncol, Vol.11 (4), pp. 579-589.  show abstract

Kasenda, B., Larkin, J. & Gore, M. (2015). Immunotherapies in Early and Advanced Renal Cell Cancer. , , pp. 1-10.

Molina, A.M., Hutson, T.E., Larkin, J., Gold, A.M., Wood, K., Carter, D., Motzer, R. & Michaelson, M.D. (2014). A phase 1b clinical trial of the multi-targeted tyrosine kinase inhibitor lenvatinib (E7080) in combination with everolimus for treatment of metastatic renal cell carcinoma (RCC). Cancer chemotherapy and pharmacology, Vol.73 (1), pp. 181-189.

Khattak, M. & Larkin, J. (2014). Sequential therapy with targeted agents in metastatic renal cell carcinoma: beyond second-line and overcoming drug resistance. World j urol, Vol.32 (1), pp. 19-29.  show abstract

Gerlinger, M., Horswell, S., Larkin, J., Rowan, A.J., Salm, M.P., Varela, I., Fisher, R., McGranahan, N., Matthews, N., Santos, C., et al. (2014). Genomic architecture and evolution of clear cell renal carcinomas defined by multiregion sequencing. Nature genetics, .  show abstract

McArthur, G.A., Chapman, P.B., Robert, C., Larkin, J., Haanen, J.B., Dummer, R., Ribas, A., Hogg, D., Hamid, O., Ascierto, P.A., et al. (2014). Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study. Lancet oncol, Vol.15 (3), pp. 323-332.  show abstract

Hutson, T.E., Bukowski, R.M., Rini, B.I., Gore, M.E., Larkin, J.M., Figlin, R.A., Barrios, C.H., Escudier, B., Lin, X., Fly, K., et al. (2014). Efficacy and safety of sunitinib in elderly patients with metastatic renal cell carcinoma. Br j cancer, Vol.110 (5), pp. 1125-1132.  show abstract

Larkin, J., Del Vecchio, M., Ascierto, P.A., Krajsova, I., Schachter, J., Neyns, B., Espinosa, E., Garbe, C., Sileni, V.C., Gogas, H., et al. (2014). Vemurafenib in patients with BRAF(V600) mutated metastatic melanoma: an open-label, multicentre, safety study. Lancet oncol, Vol.15 (4), pp. 436-444.  show abstract

Martin-Liberal, J., Lagares-Tena, L. & Larkin, J. (2014). Prospects for MEK inhibitors for treating cancer. Expert opin drug saf, Vol.13 (4), pp. 483-495.  show abstract

Turajlic, S., Furney, S.J., Stamp, G., Rana, S., Ricken, G., Oduko, Y., Saturno, G., Springer, C., Hayes, A., Gore, M., et al. (2014). Whole-genome sequencing reveals complex mechanisms of intrinsic resistance to BRAF inhibition. Ann oncol, Vol.25 (5), pp. 959-967.  show abstract

Kelderman, S., Heemskerk, B., van Tinteren, H., van den Brom, R.R., Hospers, G.A., van den Eertwegh, A.J., Kapiteijn, E.W., de Groot, J.W., Soetekouw, P., Jansen, R.L., et al. (2014). Lactate dehydrogenase as a selection criterion for ipilimumab treatment in metastatic melanoma. Cancer immunology immunotherapy, Vol.63 (5), pp. 449-458.

Gupta, A., Love, S., Schuh, A., Shanyinde, M., Larkin, J.M., Plummer, R., Nathan, P.D., Danson, S., Ottensmeier, C.H., Lorigan, P., et al. (2014). DOC-MEK: a double-blind randomized phase II trial of docetaxel with or without selumetinib in wild-type BRAF advanced melanoma. Annals of oncology, Vol.25 (5), pp. 968-974.

Martin-Liberal, J. & Larkin, J. (2014). New RAF kinase inhibitors in cancer therapy. Expert opin pharmacother, Vol.15 (9), pp. 1235-1245.  show abstract

Benson, C., Vitfell-Rasmussen, J., Maruzzo, M., Fisher, C., Tunariu, N., Mitchell, S., Al-Muderis, O., Thway, K., Larkin, J. & Judson, I., et al. (2014). A retrospective study of patients with malignant PEComa receiving treatment with sirolimus or temsirolimus: the Royal Marsden Hospital experience. Anticancer res, Vol.34 (7), pp. 3663-3668.  show abstract

Larkin, J., Fishman, M., Wood, L., Negrier, S., Olivier, K., Pyle, L., Gorbunova, V., Jonasch, E., Andrews, L. & Staehler, M., et al. (2014). Axitinib for the treatment of metastatic renal cell carcinoma: recommendations for therapy management to optimize outcomes. Am j clin oncol, Vol.37 (4), pp. 397-403.  show abstract

Nobbenhuis, M.A., Lalondrelle, S., Larkin, J. & Banerjee, S. (2014). Management of melanomas of the gynaecological tract. Curr opin oncol, Vol.26 (5), pp. 508-513.  show abstract

Furney, S.J., Turajlic, S., Stamp, G., Thomas, J.M., Hayes, A., Strauss, D., Gavrielides, M., Xing, W., Gore, M., Larkin, J., et al. (2014). The mutational burden of acral melanoma revealed by whole-genome sequencing and comparative analysis. Pigment cell & melanoma research, Vol.27 (5), pp. 835-838.

Coupe, N., Corrie, P., Hategan, M., Larkin, J., Gore, M.E., Gupta, A., Wise, A., Suter, S., Ciria, C., Love, S., et al. (2014). 1094PDA PHASE 1, DOSE ESCALATION STUDY OF PACLITAXEL WITH GSK1120212 (TRAMETINIB) FOR THE TREATMENT OF ADVANCED MELANOMA. Annals of oncology, Vol.25 (suppl_4), pp. iv379-iv379.

Schadendorf, D., Amonkar, M.M., Stroyakovskiy, D., Levchenko, E., Gogas, H., De Braud, F.G., Grob, J., Bondarenko, I., Garbe, C., Lebbe, C., et al. (2014). 1091PDCOMBI-D: QUALITY OF LIFE (QOL) IMPACT OF THE COMBINATION OF DABRAFENIB AND TRAMETINIB (D + T) VERSUS DABRAFENIB MONOTHERAPY (D) IN PATIENTS WITH BRAF V600E/K UNRESECTABLE OR METASTATIC MELANOMA IN A PHASE III TRIAL. Annals of oncology, Vol.25 (suppl_4), pp. iv377-iv377.

Gravis, G., Chanez, B., Derosa, L., Beuselinck, B., Laguerre, B., Barthelemy, P., Brachet, P.E., Lobbedez, F.J., Escudier, B., Stewart, G.D., et al. (2014). 825PIMPACT ON OVERALL SURVIVAL OF GLANDULAR METASTASIS IN PATIENTS WITH METASTATIC CLEAR CELL RENAL CELL CARCINOMA ON BEHALF OF THE RENAL CROSS CHANNEL GROUP. Annals of oncology, Vol.25 (suppl_4), pp. iv286-iv287.

Larkin, J. & Okines, A. (2014). 43INPRECISION MEDICINE IN KIDNEY CANCER AND CLINICAL TRIAL DESIGNS. Annals of oncology, Vol.25 (suppl_4), pp. iv17-iv17.

Leijen, S., Barlesi, F., Eberhardt, W.E., Martinez, G.M., Dieras, V., Schellens, J.H., Middleton, M., Calvo, E., Paz-Ares, L., Larkin, J., et al. (2014). OCULAR TOXICITIES OBSERVED WITH MEK INHIBITOR RO4987655 (CH4987655) IN A SINGLE AGENT PHASE I STUDY WITH EXTENSION IN PATIENTS WITH ADVANCED SOLID TUMORS. British journal of clinical pharmacology, Vol.78 (4), pp. 769-769.

Thian, Y., Gutzeit, A., Koh, D.-., Fisher, R., Lote, H., Larkin, J. & Sohaib, A. (2014). Revised Choi imaging criteria correlate with clinical outcomes in patients with metastatic renal cell carcinoma treated with sunitinib. Radiology, Vol.273 (2), pp. 452-461.  show abstract

Kenny, L.M., Tomasi, G., Turkheimer, F., Larkin, J., Gore, M., Brock, C.S., Mangar, S. & Aboagye, E.O. (2014). Preliminary clinical assessment of the relationship between tumor alphavbeta3 integrin and perfusion in patients studied with [18F]fluciclatide kinetics and [15O]H2O PET. Ejnmmi research, Vol.4 (1).

Larkin, J., Ascierto, P.A., Dréno, B., Atkinson, V., Liszkay, G., Maio, M., Mandalà, M., Demidov, L., Stroyakovskiy, D., Thomas, L., et al. (2014). Combined vemurafenib and cobimetinib in BRAF-mutated melanoma. N engl j med, Vol.371 (20), pp. 1867-1876.  show abstract

Long, G.V., Stroyakovskiy, D., Gogas, H., Levchenko, E., de Braud, F., Larkin, J., Garbe, C., Jouary, T., Hauschild, A., Grob, J.J., et al. (2014). Combined BRAF and MEK Inhibition versus BRAF Inhibition Alone in Melanoma. New england journal of medicine, Vol.371 (20), pp. 1877-1888.

Zimmer, L., Barlesi, F., Martinez-Garcia, M., Dieras, V., Schellens, J.H., Spano, J.-., Middleton, M.R., Calvo, E., Paz-Ares, L., Larkin, J., et al. (2014). Phase I expansion and pharmacodynamic study of the oral MEK inhibitor RO4987655 (CH4987655) in selected patients with advanced cancer with RAS-RAF mutations. Clin cancer res, Vol.20 (16), pp. 4251-4261.  show abstract

Antonia, S.J., Larkin, J. & Ascierto, P.A. (2014). Immuno-oncology combinations: a review of clinical experience and future prospects. Clin cancer res, Vol.20 (24), pp. 6258-6268.  show abstract

Sanchez-Laorden, B., Viros, A., Girotti, M.R., Pedersen, M., Saturno, G., Zambon, A., Niculescu-Duvaz, D., Turajlic, S., Hayes, A., Gore, M., et al. (2014). BRAF Inhibitors Induce Metastasis in RAS Mutant or Inhibitor-Resistant Melanoma Cells By Reactivating MEK and ERK Signaling. Science signaling, Vol.7 (318).

Fisher, R., Horswell, S., Rowan, A., Salm, M.P., de Bruin, E.C., Gulati, S., McGranahan, N., Stares, M., Gerlinger, M., Varela, I., et al. (2014). Development of synchronous VHL syndrome tumors reveals contingencies and constraints to tumor evolution. Genome biology: biology for the post-genomic era, Vol.15 (8).  show abstract

Ascierto, P.A., Grimaldi, A.M., Anderson, A.C., Bifulco, C., Cochran, A., Garbe, C., Eggermont, A.M., Faries, M., Ferrone, S., Gershenwald, J.E., et al. (2014). Future perspectives in melanoma research: meeting report from the "Melanoma Bridge", Napoli, December 5th-8th 2013. Journal of translational medicine, Vol.12.

Khattak, M.A., Bakr, F., Krzystanek, M., Szallasi, Z., Gerlinger, M., Santos, C., Swanton, C., Pickering, L.M., Gore, M.E. & Larkin, J.M., et al. (2013). Prognostic and predictive markers in metastatic renal cell carcinoma. J clin oncol, Vol.31 (7), pp. 971-972.

Larkin, J., Paine, A., Tumur, I., Cappelleri, J.C., Healey, P.J., Foley, G., Mitchell, S., Kroes, M. & Chen, C. (2013). Second-line treatments for the management of advanced renal cell carcinoma: systematic review and meta-analysis. Expert opin pharmacother, Vol.14 (1), pp. 27-39.  show abstract

Sinha, R., Edmonds, K., Newton-Bishop, J., Gore, M., Larkin, J. & Fearfield, L. (2013). Erythema Nodosum-Like Panniculitis in Patients With Melanoma Treated With Vemurafenib. Journal of clinical oncology, Vol.31 (19), pp. E320-E321.

Khattak, M.A., Fisher, R., Hughes, P., Gore, M. & Larkin, J. (2013). Ipilimumab activity in advanced uveal melanoma. Melanoma res, Vol.23 (1), pp. 79-81.  show abstract

Fisher, R., Gore, M. & Larkin, J. (2013). Current and future systemic treatments for renal cell carcinoma. Semin cancer biol, Vol.23 (1), pp. 38-45.  show abstract

Girotti, M.R., Pedersen, M., Sanchez-Laorden, B., Viros, A., Turajlic, S., Niculescu-Duvaz, D., Zambon, A., Sinclair, J., Hayes, A., Gore, M., et al. (2013). Inhibiting EGF receptor or SRC family kinase signaling overcomes BRAF inhibitor resistance in melanoma. Cancer discov, Vol.3 (2), pp. 158-167.  show abstract

Khattak, M., Fisher, R., Turajlic, S. & Larkin, J. (2013). Targeted therapy and immunotherapy in advanced melanoma: an evolving paradigm. Ther adv med oncol, Vol.5 (2), pp. 105-118.  show abstract

Ascierto, P.A., Grimaldi, A.M., Acquavella, N., Borgognoni, L., Calabro, L., Cascinelli, N., Cesano, A., Del Vecchio, M., Eggermont, A.M., Faries, M., et al. (2013). Future perspectives in melanoma research Meeting report from the "Melanoma Bridge Napoli, December 2nd-4th 2012". Journal of translational medicine, Vol.11.

Fearfield, L., Newton-Bishop, J.A., Sinha, R., Edmonds, K., Gore, M.E. & Larkin, J. (2013). Second primary melanomas on treatment with vemurafenib: reply from the authors. Br j dermatol, Vol.168 (4), pp. 888-889.

Turajlic, S., Ali, Z., Yousaf, N. & Larkin, J. (2013). Phase I/II RAF kinase inhibitors in cancer therapy. Expert opin investig drugs, Vol.22 (6), pp. 739-749.  show abstract

Furney, S.J., Turajlic, S., Stamp, G., Nohadani, M., Carlisle, A., Thomas, J.M., Hayes, A., Strauss, D., Gore, M., van den Oord, J., et al. (2013). Genome sequencing of mucosal melanomas reveals that they are driven by distinct mechanisms from cutaneous melanoma. J pathol, Vol.230 (3), pp. 261-269.  show abstract

Martinez, P., Birkbak, N.J., Gerlinger, M., McGranahan, N., Burrell, R.A., Rowan, A.J., Joshi, T., Fisher, R., Larkin, J., Szallasi, Z., et al. (2013). Parallel evolution of tumour subclones mimics diversity between tumours. J pathol, Vol.230 (4), pp. 356-364.  show abstract

Fisher, R. & Larkin, J. (2013). Individualising treatment choices in a crowded treatment algorithm. European journal of cancer supplements, Vol.11 (2), pp. 160-168.

Ali, Z., Yousaf, N. & Larkin, J. (2013). Melanoma epidemiology, biology and prognosis. European journal of cancer supplements, Vol.11 (2), pp. 81-91.

Yousaf, N. & Larkin, J. (2013). Axitinib in advanced renal-cell carcinoma. Lancet oncol, Vol.14 (13), pp. 1245-1246.

Gerlinger, M., Quezada, S.A., Peggs, K.S., Furness, A.J., Fisher, R., Marafioti, T., Shende, V.H., McGranahan, N., Rowan, A.J., Hazell, S., et al. (2013). Ultra-deep T cell receptor sequencing reveals the complexity and intratumour heterogeneity of T cell clones in renal cell carcinomas. J pathol, Vol.231 (4), pp. 424-432.  show abstract

Henrion, M., Frampton, M., Scelo, G., Purdue, M., Ye, Y., Broderick, P., Ritchie, A., Kaplan, R., Meade, A., McKay, J., et al. (2013). Common variation at 2q22 3 (ZEB2) influences the risk of renal cancer. Hum mol genet, Vol.22 (4), pp. 825-831.  show abstract

Henrion, M., Frampton, M., Scelo, G., Purdue, M., Ye, Y., Broderick, P., Ritchie, A., Kaplan, R., Meade, A., McKay, J., et al. (2013). Common variation at 2q22 3 (ZEB2) influences the risk of renal cancer. Human molecular genetics, Vol.22 (10), pp. 2128-2128.

Vasudev, N.S., Goh, V., Juttla, J.K., Thompson, V.L., Larkin, J.M., Gore, M., Nathan, P.D. & Reynolds, A.R. (2013). Changes in tumour vessel density upon treatment with anti-angiogenic agents: relationship with response and resistance to therapy. British journal of cancer, Vol.109 (5).

Karapanagiotou, E.M., Roulstone, V., Twigger, K., Ball, M., Tanay, M., Nutting, C., Newbold, K., Gore, M.E., Larkin, J., Syrigos, K.N., et al. (2012). Phase I/II trial of carboplatin and paclitaxel chemotherapy in combination with intravenous oncolytic reovirus in patients with advanced malignancies. Clin cancer res, Vol.18 (7), pp. 2080-2089.  show abstract

Pacey, S., Gore, M., Chao, D., Banerji, U., Larkin, J., Sarker, S., Owen, K., Asad, Y., Raynaud, F., Walton, M., et al. (2012). A Phase II trial of 17-allylamino, 17-demethoxygeldanamycin (17-AAG, tanespimycin) in patients with metastatic melanoma. Invest new drugs, Vol.30 (1), pp. 341-349.  show abstract

Fisher, R., Cahalin, P., Gore, M. & Larkin, J. (2012). A tale of two tumours and a plea for progress. Lancet oncol, Vol.13 (2), pp. 124-125.

Turajlic, S., Furney, S.J., Lambros, M.B., Mitsopoulos, C., Kozarewa, I., Geyer, F.C., Mackay, A., Hakas, J., Zvelebil, M., Lord, C.J., et al. (2012). Whole genome sequencing of matched primary and metastatic acral melanomas. Genome res, Vol.22 (2), pp. 196-207.  show abstract

Gruenwald, V., Karakiewicz, P.I., Bavbek, S.E., Miller, K., Machiels, J.-., Lee, S.-., Larkin, J., Bono, P., Rha, S.Y., Castellano, D., et al. (2012). An international expanded-access programme of everolimus: Addressing safety and efficacy in patients with metastatic renal cell carcinoma who progress after initial vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapy. European journal of cancer, Vol.48 (3), pp. 324-332.

Fisher, R. & Larkin, J. (2012). Treatment of brain metastases in patients with melanoma. Lancet oncol, Vol.13 (5), pp. 434-435.

Young, K., Minchom, A. & Larkin, J. (2012). BRIM-1, -2 and -3 trials: improved survival with vemurafenib in metastatic melanoma patients with a BRAF(V600E) mutation. Future oncol, Vol.8 (5), pp. 499-507.  show abstract

Gerlinger, M., Santos, C.R., Spencer-Dene, B., Martinez, P., Endesfelder, D., Burrell, R.A., Vetter, M., Jiang, M., Saunders, R.E., Kelly, G., et al. (2012). Genome-wide RNA interference analysis of renal carcinoma survival regulators identifies MCT4 as a Warburg effect metabolic target. J pathol, Vol.227 (2), pp. 146-156.  show abstract

Larkin, J., Esser, N., Calvo, E., Tsuchihashi, Z., Fiedler, U., Graeser, R. & Kim, D. (2012). Efficacy of sequential treatment with sunitinib-everolimus in an orthotopic mouse model of renal cell carcinoma. Anticancer res, Vol.32 (7), pp. 2399-2406.  show abstract

Gerlinger, M., Rowan, A.J., Horswell, S., Math, M., Larkin, J., Endesfelder, D., Gronroos, E., Martinez, P., Matthews, N., Stewart, A., et al. (2012). Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N engl j med, Vol.366 (10), pp. 883-892.  show abstract

Khattak, M., Gore, M., Larkin, J., Strauss, D., Thomas, M., Hayes, A. & Harrington, K. (2012). Adjuvant nodal irradiation in melanoma. Lancet oncol, Vol.13 (8), pp. e326-e327.

Larkin, J.M., Fisher, R.A. & Gore, M.E. (2012). Adjuvant Interferon Therapy for Patients at High Risk for Recurrent Melanoma: An Updated Systematic Review. Clinical oncology, Vol.24 (6), pp. 410-412.

Thway, K., du Parcq, J., Larkin, J.M., Fisher, C. & Livni, N. (2012). Metastatic renal mucinous tubular and spindle cell carcinoma Atypical behavior of a rare, morphologically bland tumor. Ann diagn pathol, Vol.16 (5), pp. 407-410.  show abstract

Larkin, J.M., Blank, C.U., Bono, P., Gogov, S., Panneerselvam, A., Garay, C.A., Gruenwald, V. & Grp, R.E. (2012). Everolimus in patients with metastatic renal cell carcinoma refractory to VEGF-targeted therapy: REACT subgroup analysis of prior therapy. Journal of clinical oncology, Vol.30 (5).

Blank, C.U., Bono, P., Larkin, J.M., Gogov, S., Panneerselvam, A., Garay, C.A., Gruenwald, V. & Grp, R.E. (2012). Safety and efficacy of everolimus in patients with non-clear cell renal cell carcinoma refractory to VEGF-targeted therapy: Subgroup analysis of REACT. Journal of clinical oncology, Vol.30 (5).

Larkin, J.M., Blank, C.U., Bono, P., Gogov, S., Panneerselvam, A., Garay, C.A., Grünwald, V. & REACT Study Group, (2012). Everolimus in patients with metastatic renal cell carcinoma refractory to VEGF-targeted therapy: REACT subgroup analysis of prior therapy. J clin oncol, Vol.30 (5_suppl), p. 391.  show abstract

Blank, C.U., Bono, P., Larkin, J.M., Gogov, S., Panneerselvam, A., Garay, C.A., Grünwald, V. & REACT Study Group, (2012). Safety and efficacy of everolimus in patients with non-clear cell renal cell carcinoma refractory to VEGF-targeted therapy: Subgroup analysis of REACT. J clin oncol, Vol.30 (5_suppl), p. 402.  show abstract

Khattak, M.A., Fisher, R.A., Pickering, L.M., Gore, M.E. & Larkin, J.M. (2012). Endobronchial metastases from renal cell carcinoma: a late manifestation of the disease with an increasing incidence. Bju int, Vol.110 (10), pp. 1407-1408.

Sinha, R., Edmonds, K., Newton-Bishop, J.A., Gore, M.E., Larkin, J. & Fearfield, L. (2012). Cutaneous adverse events associated with vemurafenib in patients with metastatic melanoma: practical advice on diagnosis, prevention and management of the main treatment-related skin toxicities. Br j dermatol, Vol.167 (5), pp. 987-994.  show abstract

Proskorovsky, I., Benedict, A., Larkin, J.M., Sandin, R. & Chen, C. (2012). AXITINIB (AXI) AND BEST SUPPORTIVE CARE (BSC) IN THE TREATMENT OF SUNITINIB-REFRACTORY PATIENTS WITH METASTATIC RENAL CELL CARCINOMA (MRCC): RESULTS OF A SIMULATED TREATMENT COMPARISON (STC) ANALYSES. Value in health, Vol.15 (7), pp. A410-A410.

Flaherty, K.T., Robert, C., Hersey, P., Nathan, P., Garbe, C., Milhem, M., Demidov, L.V., Hassel, J.C., Rutkowski, P., Mohr, P., et al. (2012). Improved Survival with MEK Inhibition in BRAF-Mutated Melanoma. New england journal of medicine, Vol.367 (2), pp. 107-114.

Kirkwood, J.M., Bastholt, L., Robert, C., Sosman, J., Larkin, J., Hersey, P., Middleton, M., Cantarini, M., Zazulina, V., Kemsley, K., et al. (2012). Phase II, Open-Label, Randomized Trial of the MEK1/2 Inhibitor Selumetinib as Monotherapy versus Temozolomide in Patients with Advanced Melanoma. Clinical cancer research, Vol.18 (2), pp. 555-567.

Gerlinger, M., Rowan, A., Horswell, S., Larkin, J., Endesfelder, D., Gronroos, E., Martinez, P., Matthews, N., Stewart, A., Tarpey, P., et al. (2012). Abstract 964: Intra-tumor heterogeneity and Darwinian selection revealed by multi-region exome sequencing of renal cell carcinomas. Clinical research, .

Larkin, J., Goh, X.Y., Vetter, M., Pickering, L. & Swanton, C. (2012). Epigenetic regulation in RCC: opportunities for therapeutic intervention?. Nat rev urol, Vol.9 (3), pp. 147-155.  show abstract

Swanton, C., Larkin, J. & Gerlinger, M. (2012). Intratumor Heterogeneity and Branched Evolution REPLY. New england journal of medicine, Vol.366 (22), pp. 2133-2133.

Fisher, R., Pender, A., Thillai, K., Chowdhury, S., Pickering, L., Khabra, K., Gore, M. & Larkin, J. (2012). Observation as a treatment strategy for advanced renal cell carcinoma-a call for prospective validation. Front oncol, Vol.2, p. 155.

Fisher, R. & Larkin, J. (2012). Vemurafenib: a new treatment for BRAF-V600 mutated advanced melanoma. Cancer manag res, Vol.4, pp. 243-252.  show abstract

Fisher, R., Larkin, J. & Swanton, C. (2012). Inter and intratumour heterogeneity: a barrier to individualized medical therapy in renal cell carcinoma?. Front oncol, Vol.2, p. 49.

Suwaki, N., Vanhecke, E., Atkins, K.M., Graf, M., Swabey, K., Huang, P., Schraml, P., Moch, H., Cassidy, A.M., Brewer, D., et al. (2011). A HIF-regulated VHL-PTP1B-Src signaling axis identifies a therapeutic target in renal cell carcinoma. Sci transl med, Vol.3 (85), p. 85ra47.  show abstract

Gore, M.E. & Larkin, J.M. (2011). Challenges and opportunities for converting renal cell carcinoma into a chronic disease with targeted therapies. British journal of cancer, Vol.104 (3), pp. 399-406.

Khan, O.A., Gore, M., Lorigan, P., Stone, J., Greystoke, A., Burke, W., Carmichael, J., Watson, A.J., McGown, G., Thorncroft, M., et al. (2011). A phase I study of the safety and tolerability of olaparib (AZD2281, KU0059436) and dacarbazine in patients with advanced solid tumours. British journal of cancer, Vol.104 (5), pp. 750-755.

Okera, M., Chan, S., Dernede, U., Larkin, J., Popat, S., Gilbert, D., Jones, L., Osuji, N., Sykes, H., Oakley, C., et al. (2011). A prospective study of chemotherapy-induced febrile neutropenia in the South West London Cancer Network Interpretation of study results in light of NCAG/NCEPOD findings. British journal of cancer, Vol.104 (3), pp. 407-412.

Larkin, J., Swanton, C. & Pickering, L. (2011). Optimizing treatment of metastatic renal cell carcinoma by changing mechanism of action. Expert rev anticancer ther, Vol.11 (4), pp. 639-649.  show abstract

Bex, A., Larkin, J. & Blank, C. (2011). Non-Clear Cell Renal Cell Carcinoma: How New Biological Insight May Lead to New Therapeutic Modalities. Current oncology reports, Vol.13 (3), pp. 240-248.

Fisher, R., Pickering, L. & Larkin, J. (2011). New targeted therapies for renal cell carcinoma. Expert opin investig drugs, Vol.20 (7), pp. 933-945.  show abstract

Josephs, D., Hutson, T.E., Cowey, C.L., Pickering, L.M., Larkin, J.M., Gore, M.E., Van Hemelrijck, M., McDermott, D.F., Powles, T., Chowdhury, P., et al. (2011). Efficacy and toxicity of sunitinib in patients with metastatic renal cell carcinoma with severe renal impairment or on haemodialysis. Bju international, Vol.108 (8), pp. 1279-1283.

Larkin, J.M. & Gore, M.E. (2011). Primary Excision Margins and Sentinel Lymph Node Biopsy in Clinically Node-negative Melanoma of the Trunk or Extremities. Clinical oncology, Vol.23 (9), pp. 569-571.

Minchom, A., Young, K. & Larkin, J. (2011). Ipilimumab: showing survival benefit in metastatic melanoma. Future oncol, Vol.7 (11), pp. 1255-1264.  show abstract

Sanz-Moreno, V., Gaggioli, C., Yeo, M., Albrengues, J., Wallberg, F., Viros, A., Hooper, S., Mitter, R., Féral, C.C., Cook, M., et al. (2011). ROCK and JAK1 signaling cooperate to control actomyosin contractility in tumor cells and stroma. Cancer cell, Vol.20 (2), pp. 229-245.  show abstract

Larkin, J.M., Fisher, R.A., Pickering, L.M., Sohaib, S.A., Ghosn, M., Christmas, T., Cordiner, R.L. & Gore, M.E. (2011). Chromophobe Renal Cell Carcinoma With Prolonged Response to Sequential Sunitinib and Everolimus. Journal of clinical oncology, Vol.29 (9), pp. E241-E242.

Chapman, P.B., Hauschild, A., Robert, C., Larkin, J.M., Haanen, J.B., Ribas, A., Hogg, D., O'Day, S., Ascierto, P.A., Testori, A., et al. (2011). Phase III randomized, open-label, multicenter trial (BRIM3) comparing BRAF inhibitor vemurafenib with dacarbazine (DTIC) in patients with (V600E)BRAF-mutated melanoma. Journal of clinical oncology, Vol.29 (18).

Ratnayake, G., Pender, A., Pickering, L.M., Gore, M.E. & Larkin, J.M. (2011). Intrapatient correlation of clinical benefit from VEGF and mTOR inhibition in metastatic renal cell carcinoma. Journal of clinical oncology, Vol.29 (15).

Hutson, T.E., Bukowski, R.M., Rini, B.I., Gore, M.E., Larkin, J.M., Figlin, R.A., Barrios, C.H., Escudier, B., Lin, X., Fly, K.D., et al. (2011). A pooled analysis of the efficacy and safety of sunitinib in elderly patients (pts) with metastatic renal cell carcinoma (mRCC). Journal of clinical oncology, Vol.29 (15).

Leary, A., Pickering, L.M., Larkin, J.M., Leach, M.O., Gore, M.E., Sohaib, A., Collins, D.J. & Koh, D. (2011). Quantitative diffusion-weighted (DW) MR imaging of microcapillary perfusion and tissue diffusivity as biomarkers of response of renal cell carcinoma (RCC) to treatment with sunitinib. Journal of clinical oncology, Vol.29 (15).

Fisher, R.A., Pender, A., Thillai, K., Chowdhury, S., Pickering, L.M., Rose, S.S., Gore, M.E. & Larkin, J.M. (2011). Observation prior to systemic therapy in patients with metastatic renal cell carcinoma in the kinase inhibitor era. Journal of clinical oncology, Vol.29 (15).

Chapman, P.B., Hauschild, A., Robert, C., Larkin, J.M., Haanen, J.B., Ribas, A., Hogg, D., O'Day, S., Ascierto, P.A., Testori, A., et al. (2011). Phase III randomized, open-label, multicenter trial (BRIM3) comparing BRAF inhibitor RG7204 with dacarbazine in patients with V600E BRAF-mutated melanomas. Journal of clinical oncology, Vol.29 (15).

Gruenwald, V., Karakiewicz, P.I., Bavbek, S.E., Miller, K., Machiels, J.H., Lee, S., Larkin, J.M., Bono, P., Rha, S.Y., Castellano, D.E., et al. (2011). Final results of the international, expanded-access program of everolimus in patients with advanced renal cell carcinoma who progress after prior vascular endothelial growth factor receptor-tyrosine kinase inhibitor (VEGFr-TKI) therapy. Journal of clinical oncology, Vol.29 (15).

Chapman, P.B., Hauschild, A., Robert, C., Larkin, J.M., Haanen, J.B., Ribas, A., Hogg, D., O'Day, S., Ascierto, P.A., Testori, A., et al. (2011). Phase III randomized, open-label, multicenter trial (BRIM3) comparing BRAF inhibitor vemurafenib with dacarbazine (DTIC) in patients with (V600E)BRAF-mutated melanoma. J clin oncol, Vol.29 (18_suppl), p. LBA4.  show abstract

Hutson, T.E., Bukowski, R.M., Rini, B.I., Gore, M.E., Larkin, J.M., Figlin, R.A., Barrios, C.H., Escudier, B., Lin, X., Fly, K.D., et al. (2011). A pooled analysis of the efficacy and safety of sunitinib in elderly patients (pts) with metastatic renal cell carcinoma (mRCC). J clin oncol, Vol.29 (15_suppl), p. 4604.  show abstract

Fisher, R.A., Pender, A., Thillai, K., Chowdhury, S., Pickering, L.M., St Rose, S., Gore, M.E. & Larkin, J.M. (2011). Observation prior to systemic therapy in patients with metastatic renal cell carcinoma in the kinase inhibitor era. J clin oncol, Vol.29 (15_suppl), p. 4630.  show abstract

Larkin, J.M., Turajlic, S., Nathan, P.D., Lorigan, P., Stamp, G., Gonzalez de Castro, D., Martin, N., Griffiths, J., Edmonds, K., Sarker, S., et al. (2011). A phase II trial of nilotinib in the treatment of patients with KIT mutated advanced acral and mucosal melanoma (NICAM). J clin oncol, Vol.29 (15_suppl), p. TPS229.  show abstract

Leary, A., Pickering, L.M., Larkin, J.M., Leach, M.O., Gore, M.E., Sohaib, A., Collins, D.J. & Koh, D. (2011). Quantitative diffusion-weighted (DW) MR imaging of microcapillary perfusion and tissue diffusivity as biomarkers of response of renal cell carcinoma (RCC) to treatment with sunitinib. J clin oncol, Vol.29 (15_suppl), p. TPS154.  show abstract

Ratnayake, G., Pender, A., Pickering, L.M., Gore, M.E. & Larkin, J.M. (2011). Intrapatient correlation of clinical benefit from VEGF and mTOR inhibition in metastatic renal cell carcinoma. J clin oncol, Vol.29 (15_suppl), p. e15175.  show abstract

Chapman, P.B., Hauschild, A., Robert, C., Larkin, J.M., Haanen, J.B., Ribas, A., Hogg, D., O'Day, S., Ascierto, P.A., Testori, A., et al. (2011). Phase III randomized, open-label, multicenter trial (BRIM3) comparing BRAF inhibitor RG7204 with dacarbazine in patients with V600E BRAF-mutated melanomas. J clin oncol, Vol.29 (15_suppl), p. LBA4.  show abstract

Grünwald, V., Karakiewicz, P.I., Bavbek, S.E., Miller, K., Machiels, J.H., Lee, S., Larkin, J.M., Bono, P., Rha, S.Y., Castellano, D.E., et al. (2011). Final results of the international, expanded-access program of everolimus in patients with advanced renal cell carcinoma who progress after prior vascular endothelial growth factor receptor-tyrosine kinase inhibitor (VEGFr-TKI) therapy. J clin oncol, Vol.29 (15_suppl), p. 4601.  show abstract

Chapman, P.B., Hauschild, A., Robert, C., Haanen, J.B., Ascierto, P., Larkin, J., Dummer, R., Garbe, C., Testori, A., Maio, M., et al. (2011). Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation. New england journal of medicine, Vol.364 (26), pp. 2507-2516.

Fisher, R. & Larkin, J. (2011). Renal cell cancer: what can we learn from pre-operative studies?. Front oncol, Vol.1, p. 51.

Larkin, J., Fisher, R., Pickering, L., Thway, K., Livni, N., Fisher, C. & Gore, M. (2010). Metastatic Mucinous Tubular and Spindle Cell Carcinoma of the Kidney Responding to Sunitinib. J clin oncol, Vol.28 (28), pp. E539-E540.

Rennalls, L.P., Seidl, T., Larkin, J.M., Wellbrock, C., Gore, M.E., Eisen, T. & Bruno, L. (2010). The melanocortin receptor agonist NDP-MSH impairs the allostimulatory function of dendritic cells. Immunology, Vol.129 (4), pp. 610-619.

Mukherji, D., Larkin, J. & Pickering, L. (2010). Sunitinib for metastatic renal cell carcinoma. Future oncology, Vol.6 (9), pp. 1377-1385.

Goldstein, R., Pickering, L. & Larkin, J. (2010). Does axitinib (AG-01376) have a future role in metastatic renal cell carcinoma and other malignancies?. Expert review of anticancer therapy, Vol.10 (10), pp. 1545-1557.

Larkin, J.M., Ferguson, T.R., Pickering, L.M., Edmonds, K., James, M.G., Thomas, K., Banerji, U., Berns, B., de Boer, C. & Gore, M.E., et al. (2010). A phase I/II trial of sorafenib and infliximab in advanced renal cell carcinoma. Br j cancer, Vol.103 (8), pp. 1149-1153.  show abstract

Pickering, L.M., Constantinidou, A., Larkin, J.M., Sohaib, S.A., Khatri, P., Nathan, P.D., Vinayan, A., Ferguson, T., St Rose, S. & Gore, M.E., et al. (2010). Sunitinib treatment for longer than 2 years for renal cell carcinoma. Journal of clinical oncology, Vol.28 (15).

Larkin, J.M., Hess, V., Pickering, L.M., Ferguson, T., Forrest, R. & Gore, M.E. (2010). Symptomatic brain metastases from renal cell carcinoma during treatment with sunitinib or sorafenib. Journal of clinical oncology, Vol.28 (15).

Swanton, C., Juul, N., Larkin, J.M., Eklund, A., Li, Q., Desmedt, C., Sotiriou, C., Pusztal, L. & Szallasi, Z. (2010). Use of an RNA interference screen-derived mitotic and ceramide pathway metagene to predict response to paclitaxel combination chemotherapy in primary breast cancer. Journal of clinical oncology, Vol.28 (15).

Larkin, J. & Gore, M. (2010). Is advanced renal cell carcinoma becoming a chronic disease?. Lancet, Vol.376 (9741), pp. 574-575.

Fisher, R.A. & Larkin, J. (2010). Malignant melanoma (metastatic). Bmj clin evid, Vol.2010.  show abstract

Larkin, J.M., Pyle, L.M. & Gore, M.E. (2010). Fatigue in renal cell carcinoma: the hidden burden of current targeted therapies. Oncologist, Vol.15 (11), pp. 1135-1146.  show abstract

Swanton, C., Larkin, J.M., Gerlinger, M., Eklund, A.C., Howell, M., Stamp, G., Downward, J., Gore, M., Futreal, P.A., Escudier, B., et al. (2010). Predictive biomarker discovery through the parallel integration of clinical trial and functional genomics datasets. Genome medicine, Vol.2.

Pickering, L.M., Pyle, L. & Larkin, J.M. (2009). Sunitinib is superior to interferon alpha with respect to quality of life for patients with renal cell carcinoma. Nat clin pract oncol, Vol.6 (1), pp. 6-7.  show abstract

Larkin, J.M., Clarke, R.E. & Pickering, L.M. (2009). Everolimus (RAD001) in the treatment of advanced renal cell carcinoma: biology and pathways. Medical oncology, Vol.26, pp. 40-45.

Larkin, J.M., Kipps, E.L., Powell, C.J. & Swanton, C. (2009). Systemic therapy for advanced renal cell carcinoma. Ther adv med oncol, Vol.1 (1), pp. 15-27.  show abstract

Sternberg, C.N., Bellmunt, J., Gruenwald, V., Larkin, J. & Mulders, P. (2009). Advances in the Management of Metastatic Renal Cell Cancer. European urology supplements, Vol.8 (9), pp. 758-761.

Larkin, J. & Gore, M. (2009). HEALTH POLICY The UK 'postcode lottery' in renal cell carcinoma. Nature reviews urology, Vol.6 (12), pp. 636-638.

Miller, R.E. & Larkin, J.M. (2009). Combination systemic therapy for advanced renal cell carcinoma. Oncologist, Vol.14 (12), pp. 1218-1224.  show abstract

Josephs, D.H., Hutson, T.E., Pickering, L.M., Larkin, J.M., Choueiri, T.K., Patel, T.V., Mcdermott, D.F., Powles, T., Harper, P.G. & Chowdhury, S., et al. (2009). Efficacy and toxicity of sunitinib in patients with metastatic renal cell carcinoma (mRCC) with severe renal impairment or on haemodialysis. J clin oncol, Vol.27 (15_suppl), p. 5109.  show abstract

Carden, C.P., Myerson, J.S., Popat, S., Montes, A., Larkin, J.M., Benson, M.J. & O'Brien, M.E. (2008). Good vibrations and the power of positron thinking: positron emission tomography and endoscopic ultrasound in staging of mesothelioma-two case reports. J thorac oncol, Vol.3 (5), pp. 539-541.

Carden, C.P., Larkin, J.M. & Rosenthal, M.A. (2008). What is the risk of intracranial bleeding during anti-VEGF therapy?. Neuro oncol, Vol.10 (4), pp. 624-630.  show abstract

Chowdhury, S., Larkin, J.M. & Gore, M.E. (2008). Recent advances in the treatment of renal cell carcinoma and the role of targeted therapies. European journal of cancer, Vol.44 (15), pp. 2152-2161.

Dernedde, U., Chan, S., Sykes, H., Oakley, C., Larkin, J., Popat, S., Gilbert, D., Jones, L. & Chowdhury, S. (2008). South West London Cancer Network (SWLCN) audit of patients with chemotherapy-induced febrile neutropenia (CIFN). Journal of clinical oncology, Vol.26 (15).

Larkin, J. & Gore, M. (2008). Malignant melanoma (metastatic). Bmj clin evid, Vol.2008.  show abstract

Larkin, J.M. & Porter, C.D. (2007). Complement insufficiency limits efficacy in a xenograft model of hyperacute rejection for cancer therapy. Cancer immunology immunotherapy, Vol.56 (1), pp. 60-69.

Fearfield, L.A., Larkin, J.M., Rowe, A., A'Hern, R., Fisher, C., Francis, N., MacKie, R., McCann, B., Gore, M.E. & Bunker, C.B., et al. (2007). Expression of p16, CD95, CD95L and Helix pomatia agglutinin in relapsing and nonrelapsing very thin melanoma. Brit j dermatol, Vol.156 (3), pp. 440-447.  show abstract

Larkin, J.M. (2007). Patupilone Antimitotic drug, microtubule-stabilizing agent, oncolytic. Drugs of the future, Vol.32 (4), pp. 323-336.

Larkin, J.M. & Kaye, S.B. (2007). Potential clinical applications of epothilones: a review of phase II studies. Ann oncol, Vol.18 Suppl 5, pp. v28-v34.  show abstract

Larkin, J.M., Chowdhury, S. & Gore, M.E. (2007). Drug insight: advances in renal cell carcinoma and the role of targeted therapies. Nat clin pract oncol, Vol.4 (8), pp. 470-479.  show abstract

Larkin, J.M., Hughes, S.A., Beirne, D.A., Patel, P.M., Gibbens, I.M., Bate, S.C., Thomas, K., Eisen, T.G. & Gore, M.E. (2007). A Phase I/II study of lomustine and temozolomide in patients with cerebral metastases from malignant melanoma. British journal of cancer, Vol.96 (1), pp. 44-48.

Larkin, J.M. & Eisen, T. (2006). Renal cell carcinoma and the use of sorafenib. Ther clin risk manag, Vol.2 (1), pp. 87-98.  show abstract

Larkin, J.M., Norsworth, P.J., A'Hern, R.P., Eisen, T.G., Gore, M.E. & Porter, C.D. (2006). Anti-alpha Gal-dependent complement-mediated cytotoxicity in metastatic melanoma. Melanoma res, Vol.16 (2), pp. 157-163.  show abstract

Larkin, J.M. & Kaye, S.B. (2006). Epothilones in the treatment of cancer. Expert opin inv drug, Vol.15 (6), pp. 691-702.  show abstract

Larkin, J.M. & Eisen, T. (2006). Kinase inhibitors in the treatment of renal cell carcinoma. Crit rev oncol hematol, Vol.60 (3), pp. 216-226.  show abstract

Larkin, J.M. & Porter, C.D. (2005). Mice are unsuitable for modelling ABO discordance despite strain-specific A cross-reactive natural IgM. British journal of haematology, Vol.130 (2), pp. 310-317.

Larkin, J.M. & Gore, M.E. (2005). The MRC randomised-controlled trial of interferon-alpha, interleukin-2 and 5-fluorouracil vs interferon-alpha alone in patients with advanced renal cell carcinoma (RE04): Rationale and progress. Clinical oncology, Vol.17 (5), pp. 319-321.

Kolomainen, D.F., Larkin, J.M., Badran, M., A'Hern, R.P., King, D.M., Fisher, C., Bridges, J.E., Blake, P.R., Barton, D.P., Shepherd, J.H., et al. (2002). Epithelial ovarian cancer metastasizing to the brain: a late manifestation of the disease with an increasing incidence. J clin oncol, Vol.20 (4), pp. 982-986.  show abstract

Gulati, S., Martinez, P., Joshi, T., Birbak, N.J., Santos, C.R., Rowan, A.J., Pickering, L., Gore, M., Larkin, J., Szallasi, Z., et al. Systematic Evaluation of the Prognostic Impact and Intratumour Heterogeneity of Clear Cell Renal Cell Carcinoma Biomarkers. European urology, .  show abstract

Henrion, M.Y., Purdue, M.P., Scelo, G., Broderick, P., Frampton, M., Ritchie, A., Meade, A., Li, P., McKay, J., Johansson, M., et al. Common Variation at 1q24 1 (ALDH9A1) Is a Potential Risk Factor for Renal Cancer. Plos one, Vol.10 (3), pp. e0122589-e0122589.

Biondo, A., Alexander, H., Khabra, K., Pickering, L., Gore, M. & Larkin, J. Pazopanib-Induced Alopecia, an Underestimated Toxicity?. Frontiers in oncology, Vol.5.

Argyropulo-Palmer, M., Jenkins, A., Theti, D.S., Larkin, J. & Montgomery, D. Sunitinib in Metastatic Renal Cell Carcinoma: A Systematic Review of UK Real World Data. Frontiers in oncology, Vol.5.

Larkin, J., Hatswell, A.J., Nathan, P., Lebmeier, M. & Lee, D. The Predicted Impact of Ipilimumab Usage on Survival in Previously Treated Advanced or Metastatic Melanoma in the UK. Plos one, Vol.10 (12), pp. e0145524-e0145524.

Reynolds, A., bridgeman, V., vermeulen, P., foo, S., bilezc, A., daley, F., kostaras, E., nathan, M., wan, E., frentzas, S., et al. Vessel co-option is common in human lung metastases and mediates resistance to anti-angiogenic therapy in preclinical lung metastasis models. Journal of pathology, .

O’Reilly, A. & Larkin, J. Lenvatinib for use in combination with everolimus for the treatment of patients with advanced renal cell carcinoma following one prior anti-angiogenic therapy. Expert review of clinical pharmacology, , pp. 1-12.

Spain, L., Walls, G., Julve, M., O’Meara, K., Schmid, T., Kalaitzaki, E., Turajlic, S., Gore, M., Rees, J. & Larkin, J., et al. Neurotoxicity from immune-checkpoint inhibition in the treatment of melanoma: a single centre experience and review of the literature. Annals of oncology, , pp. mdw558-mdw558.


Conferences

Hirata, E., Girotti, M.R., Viros, A., Hooper, S., Spencer-Dene, B., Matsuda, M., Larkin, J., Marais, R. & Sahai, E. (2015). Intravital imaging reveals how BRaf inhibition generates drug tolerant microenvironments., JOURNAL OF NUCLEAR MEDICINE, Vol.56 (2), p.26.

Ribas, A., Schachter, J., Long, G.V., Arance, A., Grob, J.J., Mortier, L., Daud, A., Carlino, M.S., McNeil, C., Lotem, M., et al. (2015). Abstract CT101: Phase III study of pembrolizumab (MK-3475) versus ipilimumab in patients with ipilimumab-naive advanced melanoma, Presented at Proceedings: AACR 106th Annual Meeting 2015; April 18-22, 2015; Philadelphia, PA, Clinical Trials, .

Sinha, R., Larkin, J., Gore, M.E. & Fearfield, L. (2015). Incidence and management of skin-related adverse events associated with vemurafenib in BRAF V600E-positive metastatic melanoma: a 3-year retrospective cohort study of 107 patients, BRITISH JOURNAL OF DERMATOLOGY, Vol.173, p.5.

Thomas, C., Mortimer, P.S., Larkin, J.M., Basu, T.N., Gore, M.E. & Fearfield, L. (2015). Skin toxicity and oedema in metastatic melanoma treated with mitogen-activated protein kinase kinase inhibitors, BRITISH JOURNAL OF DERMATOLOGY, Vol.173, pp.59-60.

Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J.J., Cowey, C.L., Lao, C.D., Wagstaff, J., Hogg, D., Hill, A., Carlino, M.S., et al. (2015). 3303 Efficacy and safety in key patient subgroups of nivolumab (NIVO) alone or combined with ipilimumab (IPI) versus IPI alone in treatment-naïve patients with advanced melanoma (MEL) (CheckMate 067), European Journal of Cancer, Vol.51, pp.S664-S665.

McArthur, G., Larkin, J., Dréno, B., Ascierto, P., Liszkay, G., Maio, M., Mandal´, M., Demidov, L., Stroyakovskiy, D., Thomas, L., et al. (2015). 25LBA Impact of baseline genetic heterogeneities on progression-free survival (PFS) in patients (pts) with advanced BRAFV600-mutated melanoma treated with cobimetinib (COBI) + vemurafenib (VEM) in the phase 3 coBRIM study, European Journal of Cancer, Vol.51, pp.S722-S723.

Glen, H., Hsieh, J., Michaelson, M.D., Kim, H.J., Sachdev, P., Kadowaki, T., Funahashi, Y., Larkin, J. & Motzer, R. (2015). 432 Correlative analyses of serum biomarkers and clinical outcomes in the phase 2 study of lenvatinib, everolimus, and the combination, in patients with metastatic renal cell carcinoma following 1 VEGF-targeted therapy, European Journal of Cancer, Vol.51, p.S89.

Wolchok, J.D., Chiarion-Sileni, V., Gonzalez, R., Rutkowski, P., Grob, J., Cowey, C.L., Lao, C.D., Schadendorf, D., Ferrucci, P.F., Smylie, M., et al. (2015). CheckMate 067: a phase III randomized double-blind study of nivolumab (NIVO) monotherapy or NIVO combined with ipilimumab (IPI) versus IPI monotherapy in previously untreated patients (pts) with advanced melanoma (MEL), ANNALS OF ONCOLOGY, Vol.26, p.28.

Hammers, H.J., Plimack, E.R., Sternberg, C., McDermott, D.F., Larkin, J.M., Ravaud, A., Rini, B.I., Sharma, P., Bhagavatheeswaran, P., Gagnier, P., et al. (2015). CheckMate 214: A phase III, randomized, open-label study of nivolumab combined with ipilimumab versus sunitinib monotherapy in patients with previously untreated metastatic renal cell carcinoma., Journal of Clinical Oncology, Vol.33 (15_suppl), p.TPS4578.

De La Cruz-Merino, L., Di Guardo, L., Grob, J.-., Venosa, A., Larkin, J.M., McArthur, G.A., Ribas, A., Eng, S., Hsu, J.J., Barteselli, G., et al. (2015). Clinical features of cobimetinib (COBI)-associated serous retinopathy (SR) in BRAF-mutated melanoma patients (pts) treated in the coBRIM study, JOURNAL OF CLINICAL ONCOLOGY, Vol.33 (15).

Larkin, J.M., Yan, Y., McArthur, G.A., Ascierto, P.A., Liszkay, G., Maio, M., Mandala, M., Demidov, L.V., Stroyakovskiy, D., Thomas, L., et al. (2015). Update of progression-free survival (PFS) and correlative biomarker analysis from coBRIM: Phase III study of cobimetinib (cobi) plus vemurafenib (vem) in advanced BRAF-mutated melanoma., JOURNAL OF CLINICAL ONCOLOGY, Vol.33 (15).

Colomba, E., Albiges, L., Le Teuff, G., Eisen, T., Stewart, G., Fife, K., Srinivasan, A., Larkin, J.M., Biondo, A., Pickering, L.M., et al. (2015). Metastatic chromophobe renal cell carcinoma treated with target therapies: A Renal Cross Chanel Group (RCCG) study., JOURNAL OF CLINICAL ONCOLOGY, Vol.33 (15).

Long, G.V., Stroyakovskiy, D., Gogas, H., Levchenko, E., De Braud, F.G., Larkin, J.M., Garbe, C., Jouary, T., Hauschild, A., Grob, J.J., et al. (2015). Overall survival in COMBI-d, a randomized, double-blinded, phase III study comparing the combination of dabrafenib and trametinib with dabrafenib and placebo as first-line therapy in patients (pts) with unresectable or metastatic BRAF V600E/Kmutation-positive cutaneous melanoma., Journal of Clinical Oncology, Vol.33 (15_suppl), p.102.

Wolchok, J.D., Chiarion-Sileni, V., Gonzalez, R., Rutkowski, P., Grob, J.J., Cowey, C.L., Lao, C.D., Schadendorf, D., Ferrucci, P.F., Smylie, M., et al. (2015). Efficacy and safety results from a phase III trial of nivolumab (NIVO) alone or combined with ipilimumab (IPI) versus IPI alone in treatment-naive patients (pts) with advanced melanoma (MEL) (CheckMate 067)., JOURNAL OF CLINICAL ONCOLOGY, Vol.33 (15).

Dreno, B., Bartley, K., Ascierto, P.A., Atkinson, V., Liszkay, G., Maio, M., Mandala, M., Demidov, L.V., Stroyakovskiy, D., Thomas, L., et al. (2015). Quality-of-life (QOL) assessment in patients (pts) with metastatic melanoma receiving vemurafenib (V) and cobimetinib (C)., JOURNAL OF CLINICAL ONCOLOGY, Vol.33 (15).

Motzer, R., Hutson, T., Glen, H., Michaelson, D., Molina, A.M., Eisen, T., Jassem, J., Zolnierek, J., Maroto, P., Mellado, B., et al. (2015). Randomized phase II, three-arm trial of lenvatinib (LEN), everolimus (EVE), and LEN+EVE in patients (pts) with metastatic renal cell carcinoma (mRCC)., Journal of Clinical Oncology, Vol.33 (15_suppl), p.4506.

Weber, J.S., Antonia, S.J., Topalian, S.L., Schadendorf, D., Larkin, J.M., Sznol, M., Liu, H.Y., Waxman, I. & Robert, C. (2015). Safety profile of nivolumab (NIVO) in patients (pts) with advanced melanoma (MEL): A pooled analysis., JOURNAL OF CLINICAL ONCOLOGY, Vol.33 (15).

Wolchok, J.D., Chiarion-Sileni, V., Gonzalez, R., Rutkowski, P., Grob, J.J., Cowey, C.L., Lao, C.D., Schadendorf, D., Ferrucci, P.F., Smylie, M., et al. (2015). Efficacy and safety results from a phase III trial of nivolumab (NIVO) alone or combined with ipilimumab (IPI) versus IPI alone in treatment-naive patients (pts) with advanced melanoma (MEL) (CheckMate 067), JOURNAL OF CLINICAL ONCOLOGY, Vol.33 (18).

Flechsig, S., Wulf-Goldenberg, A., Schmees, C., Jandrig, B., Hennenlotter, J., Bedke, J., Schostak, M., Crockford, A., Gerlinger, M., Larkin, J., et al. (2014). Abstract 1192: Establishment and characterization of a new patient-derived renal cell carcinoma xenograft panel, Presented at Proceedings: AACR Annual Meeting 2014; April 5-9, 2014; San Diego, CA, Tumor Biology, .

Weber, J.S., Minor, D.R., D'Angelo, S.P., Hodi, F.S., Gutzmer, R., Neyns, B., Hoeller, C., Khushalani, N.I., Miller, W.H., Grob, J.-., et al. (2014). A PHASE 3 RANDOMIZED, OPEN-LABEL STUDY OF NIVOLUMAB (ANTI-PD-1; BMS-936558; ONO-4538) VERSUS INVESTIGATOR'S CHOICE CHEMOTHERAPY (ICC) IN PATIENTS WITH ADVANCED MELANOMA AFTER PRIOR ANTI-CTLA-4 THERAPY, ANNALS OF ONCOLOGY, Vol.25.

Larkin, J. & Okines, A. (2014). PRECISION MEDICINE IN KIDNEY CANCER AND CLINICAL TRIAL DESIGNS, ANNALS OF ONCOLOGY, Vol.25.

Powles, T., Hawkins, R., Ralph, C., Larkin, J., Jones, R.J., Chowdhury, S., Boleti, E., Fife, K., Bahl, A., Crabb, S., et al. (2014). A RANDOMISED PHASE II STUDY OF CEDIRANIB WITH OR WITHOUT SRC INHIBITION (SARACATINIB) IN METASTATIC CLEAR CELL RENAL CANCER (RCC) PATIENTS RESISTANT TO VEGF TARGETED THERAPY, ANNALS OF ONCOLOGY, Vol.25.

Hammers, H., Sternberg, C., Mcdermott, D.F., Larkin, J., Ravaud, A., Rini, B., Sharma, P., Bhagavatheeswaran, P., Gagnier, P. & Motzer, R., et al. (2014). A phase 3, randomized, open-label study of nivolumab combined with ipilimumab versus sunitinib monotherapy in subjects with previously untreated metastatic renal cell carcinoma, BJU INTERNATIONAL, Vol.114, p.9.

Middleton, M., Rasco, D.W., Olszanski, A.J., Corrie, P., Lorigan, P., Plummer, R., Larkin, J., Pavlick, A., Zhou, X., Yuan, Z., et al. (2014). First-in-human phase 1 study of MLN2480, an investigational oral pan-RAF kinase inhibitor, in patients (pts) with relapsed or refractory solid tumors, including BRAF/NRAS-mutant melanoma, EUROPEAN JOURNAL OF CANCER, Vol.50, p.117.

Fisher, R.A., Rowan, A., Stares, M., Webster-Smith, M.F., Lewis, R., Kilburn, L.S., Nicol, D., Stewart, G., Michael, A., Vasudev, N., et al. (2014). A-PREDICT: A phase II study of axitinib in patients with metastatic renal cell cancer unsuitable for nephrectomy (CRUKE/11/061)., Journal of Clinical Oncology, Vol.32 (15_suppl), p.TPS4597.

Gogas, H., Schadendorf, D., Dummer, R., Garbe, C., Lebbe, C., Nathan, P.D., Larkin, J.M., Haydon, A.M., Bafaloukos, D. & Robert, C., et al. (2014). Vemurafenib treatment in patients with BRAF-mutated melanoma failing MEK inhibition with trametinib., Journal of Clinical Oncology, Vol.32 (15_suppl), p.9061.

Piperno-Neumann, S., Kapiteijn, E., Larkin, J.M., Carvajal, R.D., Luke, J.J., Seifert, H., Roozen, I., Zoubir, M., Ramkumar, T., Emery, C., et al. (2014). Landscape of genetic alterations in patients with metastatic uveal melanoma., Journal of Clinical Oncology, Vol.32 (15_suppl), p.9043.

Long, G.V., Stroyakovsky, D.L., Gogas, H., Levchenko, E., de Braud, F., Larkin, J.M., Garbe, C., Jouary, T., Hauschild, A., Grob, J.J., et al. (2014). COMBI-d: A randomized, double-blinded, Phase III study comparing the combination of dabrafenib and trametinib to dabrafenib and trametinib placebo as first-line therapy in patients (pts) with unresectable or metastatic BRAFV600E/K mutation-positive cutaneous melanoma, Journal of Clinical Oncology, Vol.32 (15_suppl), p.9011.

Piperno-Neumann, S., Kapiteijn, E., Larkin, J.M., Carvajal, R.D., Luke, J.J., Seifert, H., Roozen, I., Zoubir, M., Yang, L., Choudhury, S., et al. (2014). Phase I dose-escalation study of the protein kinase C (PKC) inhibitor AEB071 in patients with metastatic uveal melanoma., Journal of Clinical Oncology, Vol.32 (15_suppl), p.9030.

Rini, B.I., Dorff, T.B., Elson, P., Suarez, C., Humbert, J., Pyle, L., Larkin, J.M. & Plimack, E.R. (2014). A prospective observational study of metastatic renal cell carcinoma (mRCC) prior to initiation of systemic therapy., Journal of Clinical Oncology, Vol.32 (15_suppl), p.4520.

Salmon, N., Fearfield, L.A., Gore, M. & Larkin, J. (2013). Metastatic basal cell carcinoma, BRITISH JOURNAL OF DERMATOLOGY, Vol.169, p.20.

Larkin, J., Paine, A., Foley, G., Mitchell, S.A. & Chen, C. (2013). First-line treatment in the management of advanced renal cell carcinoma: Systematic review and network meta-analysis, EUROPEAN JOURNAL OF CANCER, Vol.49, p.S656.

Gogas, H., Schadendorf, D., Dummer, R., Garbe, C., Lebbe, C., Nathan, P., Larkin, J., Haydon, A., Bafaloukos, D. & Robert, C., et al. (2013). Vemurafenib treatment in patients with BRAF mutated melanoma failing MEK inhibition with trametinib, EUROPEAN JOURNAL OF CANCER, Vol.49, pp.S866-S867.

Girotti, M.R., Pedersen, M., Sanchez-Laorden, B., Viros, A., Turajlic, S., Niculescu-Duvaz, D., Zambon, A., Sinclair, J., Hayes, A., Gore, M., et al. (2013). Inhibiting EGF receptor or SRC family kinase signaling overcomes BRAF inhibitor resistance in melanoma, CANCER RESEARCH, Vol.73 (8).

Das Thakur, M., Fisher, R., Salangsang, F., Landman, A., Sellers, W., Pryer, N., Levesque, M.P., Dummer, R., Gore, M., Larkin, J., et al. (2013). Modeling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance., CANCER RESEARCH, Vol.73 (8).

Molina, A.M., Hutson, T.E., Larkin, J.M., Gold, A., Andresen, C., Wood, K., Motzer, R.J. & Michaelson, M.D. (2013). A phase Ib clinical trial of the multitargeted kinase inhibitor lenvatinib (E7080) in combination with everolimus for treatment of metastatic renal cell carcinoma (RCC), JOURNAL OF CLINICAL ONCOLOGY, Vol.31 (6).

Blank, C.U., Kelderman, S., van Tinteren, H., Heemskerk, B., van den Brom, R., Hospers, G.A., van den Eertwegh, A.J., Kapiteijn, E., De Groot, J.W., Jansen, R.L., et al. (2013). Serum lactate dehydrogenase (LDH) as a prognostic selection criterion for ipilimumab treatment in metastatic melanoma, JOURNAL OF CLINICAL ONCOLOGY, Vol.31 (15).

Larkin, J.M., Del Vecchio, M., Ascierto, P.A., Schachter, J., Garbe, C., Neyns, B., Mandala, M., Lorigan, P., Miller, W.H., Guminski, A.D., et al. (2013). Open-label, multicenter safety study of vemurafenib in patients with BRAF(V600) mutation-positive metastatic melanoma, JOURNAL OF CLINICAL ONCOLOGY, Vol.31 (15).

Ahmad, S., Qian, W., Ellis, S.G., Khattak, M.A., Gupta, A., Thillai, K., Board, R.E., Nobes, J., Dalgleish, A., Grumett, S.A., et al. (2013). Ipilimumab in the real world: The UK expanded access programme (EAP) experience in advanced melanoma., JOURNAL OF CLINICAL ONCOLOGY, Vol.31 (15).

Sacco, J.J., Nathan, P.D., Danson, S., Lorigan, P., Nicholson, S., Ottensmeier, C., Corrie, P., Steven, N., Goodman, A., Larkin, J.M., et al. (2013). Sunitinib versus dacarbazine as first-line treatment in patients with metastatic uveal melanoma, JOURNAL OF CLINICAL ONCOLOGY, Vol.31 (15).

Gupta, A., Love, S., Schuh, A., Collins, L., Thomason, A., Asher, R., Lisle, R., Churchman, M., Shanyinde, M., Plummer, R., et al. (2013). DOC-MEK: A double-blind randomized phase II trial of docetaxel with or without selumetinib (AZD6244; ARRY-142886) in wt BRAF advanced melanoma, JOURNAL OF CLINICAL ONCOLOGY, Vol.31 (15).

Schadendorf, D., Flaherty, K., Hersey, P., Nathan, P.D., Garbe, C., Milhem, M.M., Demidov, L.V., Hassel, J.C., Rutkowski, P., Mohr, P., et al. (2013). Tumor-specific circulating cell-free DNA (cfDNA) to predict clinical outcome in BRAF V600 mutation-positive melanoma patients (pts) treated with the MEK inhibitor trametinib (T) or chemotherapy (C), JOURNAL OF CLINICAL ONCOLOGY, Vol.31 (15).

Hutson, T.E., Bukowski, R., Rini, B.I., Gore, M.E., Larkin, J.M., Figlin, R.A., Barrios, C.H., Escudier, B., Lin, X., Fly, K., et al. (2012). A pooled analysis of the efficacy and safety of sunitinib in elderly patients with metastatic renal cell carcinoma (mRCC), BJU INTERNATIONAL, Vol.109, pp.5-6.

Sinha, R., Edmonds, K., Newton-Bishop, J.A., Gore, M., Larkin, J. & Fearfield, L.A. (2012). Cutaneous adverse events associated with vemurafenib in patients with BRAF V600E mutation-positive metastatic melanoma: an observational study of 30 treated patients and presentation of a management algorithm, BRITISH JOURNAL OF DERMATOLOGY, Vol.167, pp.9-10.

Khattak, M.A., Edmonds, K., Khabra, K., Sohaib, A., Pennert, K., Pickering, L., Gore, M.E. & Larkin, J. (2012). INTERIM RESULTS OF A PHASE II STUDY OF SUNITINIB AND LOW DOSE METRONOMIC CYCLOPHOSPHAMIDE IN ADVANCED RENAL CELL CANCER, ANNALS OF ONCOLOGY, Vol.23, pp.273-274.

Molina, A.M., Hutson, T.E., Larkin, J., Gold, A., Andresen, C., Wood, K., Motzer, R.J. & Michaelson, M.D. (2012). A PHASE IB CLINICAL TRIAL OF THE MULTITARGETED KINASE INHIBITOR LENVATINIB (E7080) IN COMBINATION WITH EVEROLIMUS FOR TREATMENT OF METASTATIC RENAL CELL CARCINOMA (RCC), ANNALS OF ONCOLOGY, Vol.23, p.269.

Proskorovsky, I., Benedict, A., Negrier, S., Larkin, J., Sandin, R. & Chen, C. (2012). AXITINIB (AXI) AND EVEROLIMUS (EVE) IN THE TREATMENT (TX) OF SUNITINIB-REFRACTORY (SU-R) PATIENTS (PTS) WITH METASTATIC RENAL CELL CARCINOMA (MRCC): RESULTS OF A SIMULATED TX COMPARISON (STC) ANALYSES, ANNALS OF ONCOLOGY, Vol.23, p.279.

Blank, C., Del Vecchio, M., Ascierto, P.A., Queirolo, P., Hauschild, A., Arance, A., Brown, M., Mitchell, L., Veronese, L. & Larkin, J., et al. (2012). AN OPEN-LABEL, MULTICENTRE SAFETY STUDY OF VEMURAFENIB IN PATIENTS WITH METASTATIC MELANOMA, ANNALS OF ONCOLOGY, Vol.23, p.366.

Chowdhury, S. & Larkin, J. (2012). EVEROLIMUS IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA WHO PROGRESS AFTER INITIAL VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-TYROSINE KINASE INHIBITOR (VEGFR-TKI) THERAPY: UK RESULTS FROM THE REACT TRIAL ON BEHALF OF THE UK REACT INVESTIGATORS, ANNALS OF ONCOLOGY, Vol.23, pp.271-272.

Shaw, H., Larkin, J., Corrie, P., Ellis, S., Nobes, J., Marshall, E., Kumar, S., Danson, S., Plummer, R. & Nathan, P., et al. (2012). IPILIMUMAB FOR ADVANCED MELANOMA IN AN EXPANDED ACCESS PROGRAMME (EAP): OCULAR, MUCOSAL AND ACRAL SUBTYPE UK EXPERIENCE, ANNALS OF ONCOLOGY, Vol.23, p.374.

Pedersen, J.V., Benson, C., Tunariu, N., Mitchell, S., Fisher, C., Thway, K., Larkin, J.M., Scurr, M. & Judson, I.R. (2012). A retrospective study from the Royal Marsden Hospital (RMH) of patients with malignant perivascular epithelioid cell tumors (PEComa) receiving treatment with sirolimus (SI) or temsirolimus (TSI), JOURNAL OF CLINICAL ONCOLOGY, Vol.30 (15).

Larkin, J.M., Queirolo, P., Arance, A.M., Brown, M.P., Hauschild, A., Del Vecchio, M., McArthur, G.A., Neyns, B., Becker, J.C., Hansson, J., et al. (2012). An open-label, multicenter safety study of vemurafenib (PLX4032, RO5185426) in patients with metastatic melanoma., JOURNAL OF CLINICAL ONCOLOGY, Vol.30 (15).

Robert, C., Flaherty, K.T., Hersey, P., Nathan, P.D., Garbe, C., Milhem, M.M., Demidov, L.V., Hassel, J.C., Rutkowski, P., Mohr, P., et al. (2012). METRIC phase III study: Efficacy of trametinib (T), a potent and selective MEK inhibitor (MEKi), in progression-free survival (PFS) and overall survival (OS) compared with chemotherapy (C) in patients (pts) with BRAF(V600/k) mutant advanced or metastatic melanoma (MM), JOURNAL OF CLINICAL ONCOLOGY, Vol.30 (15).

Chapman, P.B., Hauschild, A., Robert, C., Larkin, J.M., Haanen, J.B., Ribas, A., Hogg, D., Hamid, O., Ascierto, P.A., Testori, A., et al. (2012). Updated overall survival (OS) results for BRIM-3, a phase III randomized, open-label, multicenter trial comparing BRAF inhibitor vemurafenib (vem) with dacarbazine (DTIC) in previously untreated patients with BRAF(V600E)-mutated melanoma., JOURNAL OF CLINICAL ONCOLOGY, Vol.30 (15).

Molina, A.M., Motzer, R.J., Hutson, T.E., Larkin, J.M., Gold, A., Andresen, C., Wood, K. & Michaelson, M.D. (2012). Treatment of refractory metastatic renal cell carcinoma (RCC) with lenvatinib (E7080) and everolimus, JOURNAL OF CLINICAL ONCOLOGY, Vol.30 (15).

Robert, C., Flaherty, K.T., Hersey, P., Nathan, P.D., Garbe, C., Milhem, M.M., Demidov, L.V., Hassel, J.C., Rutkowski, P., Mohr, P., et al. (2012). METRIC phase III study: Efficacy of trametinib (T), a potent and selective MEK inhibitor (MEKi), in progression-free survival (PFS) and overall survival (OS), compared with chemotherapy (C) in patients (pts) with BRAF(V600E/K) mutant advanced or metastatic melanoma (MM), JOURNAL OF CLINICAL ONCOLOGY, Vol.30 (18).

Marshall, E., Coupland, S., Corrie, P., Damato, B., Danson, S., Dobson, L., Evans, T.R., Goodman, A., Kalirai, H., Jones, S., et al. (2012). A randomized phase II study of sunitinib versus dacarbazine in the treatment of patients with metastatic uveal melanoma., JOURNAL OF CLINICAL ONCOLOGY, Vol.30 (15).

Plimack, E.R., Nemec, C., Elson, P., Suarez, C., Dorff, T.B., Larkin, J.M., McAleer, C., Nunez, I., Fisher, R.A. & Rini, B.I., et al. (2012). An observational study of metastatic renal cell carcinoma patients prior to initiation of initial systemic therapy, JOURNAL OF CLINICAL ONCOLOGY, Vol.30 (15).

Dudderidge, T.J., Beatty, J., Larkin, J., Gore, M. & Christmas, T.J. (2011). Surgery for loco-regional recurrence after nephrectomy for renal cell carcinoma (RCC): outcomes after initial incomplete resection and implantational recurrences, BJU INTERNATIONAL, Vol.108, p.42.

Sinha, R., Fearfield, L. & Larkin, J. (2011). A case series of BRAF V600E inhibitor (PLX4032) related cutaneous eruptions in metastatic melanoma, BRITISH JOURNAL OF DERMATOLOGY, Vol.165, p.19.

Larkin, J., Blank, C., Bono, P., Kim, D., Panneerselvam, A. & Gruenwald, V. (2011). The REACT Expanded-access Program of Everolimus in Patients With Metastatic Renal Cell Carcinoma Refractory to VEGF-targeted Therapy: Subgroup Analyses by Prior Therapy, EUROPEAN JOURNAL OF CANCER, Vol.47, p.S519.

Albiges, L., Iacovelli, R., Porta, C., Houede, N., Laguerre, B., Procopio, G., Lheureux, S., Larkin, J., Negrier, S. & Escudier, B., et al. (2011). Prognosis of Patients With Metastatic Renal Cell Carcinoma (mRCC) With Primary Resistance to Sunitinib: Is There Any Active Treatment?, EUROPEAN JOURNAL OF CANCER, Vol.47, p.S518.

Blank, C., Bono, P., Larkin, J., Kim, D., Panneerselvam, A. & Gruenwald, V. (2011). Safety and Efficacy of Everolimus in Patients With Non-clear Cell Renal Cell Carcinoma Refractory to VEGF-targeted Therapy - a Subgroup Analysis of the REACT Expanded-access Program, EUROPEAN JOURNAL OF CANCER, Vol.47, p.S516.

Larkin, J.M., Turajlic, S., Nathan, P.D., Lorigan, P., Stamp, G., de Castro, D.G., Martin, N., Griffiths, J., Edmonds, K., Sarker, S., et al. (2011). A phase II trial of nilotinib in the treatment of patients with KIT mutated advanced acral and mucosal melanoma (NICAM)., JOURNAL OF CLINICAL ONCOLOGY, Vol.29 (15).

Grunwald, V., Miller, K., Machiels, J., Lee, S., Larkin, J., Yuan, R., Rosamilia, M., Booth, J. & Karakiewicz, P. (2010). AN INTERNATIONAL EXPANDED ACCESS PROGRAM (EAP) OF EVEROLIMUS IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA (MRCC) WHO ARE INTOLERANT OF OR HAVE PROGRESSED AFTER PRIOR VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-TYROSINE KINASE INHIBITOR (VEGFR-TKI) THERAPY, ANNALS OF ONCOLOGY, Vol.21, p.274.

Christmas, T.J., Dudderidge, T., Beatty, J., Larkin, J., Gore, M. & Moat, N. (2010). Long Term Results of Surgery for Renal Tumours with Venous Extension, BJU INTERNATIONAL, Vol.106 (1), p.47.

Christmas, T.J., Agrawal, S., Savage, P., Larkin, J. & Gore, M. (2010). Laparoscopic and Open Radical Nephrectomy for Renal Carcinoma. Are They Oncologically Equivalent? A Comparison Using Loco-Regional Recurrence Data, BJU INTERNATIONAL, Vol.106 (1), p.46.

Josephs, D.H., Hutson, T.E., Pickering, L.M., Larkin, J.M., Choueiri, T.K., Patel, T.V., Mcdermott, D.F., Powles, T., Harper, P.G. & Chowdhury, S., et al. (2009). Efficacy and toxicity of sunitinib in patients with metastatic renal cell carcinoma (mRCC) with severe renal impairment or on haemodialysis, JOURNAL OF CLINICAL ONCOLOGY, Vol.27 (15).

Gerlinger, M., Horswell, S., Larkin, J., Rowan, A.J., Martinez, P., Varela, I., Santos, C.R., Fisher, R., Salm, M.P., Szallasi, Z., et al. Intratumor heterogeneity in clear cell renal cell carcinoma (ccRCC): Multi-region sequencing redefines the mutational landscape of ccRCCs, Presented at AACR Annual Meeting, Washington. .

In this section

Research overview Research projects Publications